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Abstract
Vascular Consequences of Metabolic Syndrome Related Shifts in
Cyclooxygenase Mediated Arachidonic Acid Metabolism
Adam G. Goodwill
The metabolic syndrome is a multi-faceted disease state in which the initial
pathology of obesity leads to the development of a cadre of comorbidities including, but
not limited to, atherogenic dyslipidemia, a prothrombotic state, a proinflammatory state,
a pro-oxidant state, hypertension and type II diabetes mellitus.

The prevalence of

obesity is drastically increasing both nationally and globally, indicating that
understanding obesity related disease is more relevant now then ever before. The
metabolic syndrome has been demonstrated to result in numerous deleterious
consequences for afflicted individuals, not the least of which is peripheral vascular
disease.

While the study of peripheral vascular disease has been extensively

conducted and a robust body of literature exists implicating alterations in vasomotor
regulation as the etiology for demand:perfusion mismatches in peripheral tissues, little
study has been conducted to determine the consequences of metabolic syndrome on
vascular network structure and the perfusion outcomes of the alterations to that
network.
Our lab has previously demonstrated that with metabolic syndrome comes a
progressive loss of microvessel density in skeletal muscle, termed rarefaction. This
rarefactive phenomenon has been established in other animal models as well as in
humans, however, the mechanistic underpinnings of microvascular rarefaction still
require significant investigation. For this reason we set out to:

1. Identify the significant physiologic correlates/predictors of microvascular
rarefaction.
2. Determine which correlates played a contributing role in the development of
rarefaction.
3. Better establish a time-course for the phenomenon of rarefaction in our
experimental model; the obese Zucker rat.
The results of these studies demonstrate that alterations to inflammatory status and
elevated oxidant stress significantly contribute to the development of obesity related
rarefaction. Additionally, these two causative-agents act through intermediaries either
shifting the balance in endogenous prostanoid production to a preferential generation of
TxA2, or diminishing vascular nitric oxide bioavailability. Additionally, it was discovered
that in the obese Zucker rat, rarefaction is a biphasic process wherein the phases are
mechanistically distinct from one another. The initial or early phase of rarefaction is
mediated by elevations in TxA2 production, whereas later rarefaction is mediated by
diminished vascular nitric oxide bioavailability. Taken together, these data indicate that
rarefaction is a process whose origins are rooted in the very earliest development of
metabolic syndrome. The process itself is more mechanistically complex than initially
anticipated and is mediated by pathologic alterations (elevated oxidant stress and
altered inflammatory profile) which have been shown to produce additional deleterious
effects.

These studies would indicate that a greater knowledge of the origins and

regulation of alterations to inflammatory status and elevations in oxidative stress are
essential in treating metabolic syndrome.
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Chapter 1

The Metabolic Syndrome

1

The metabolic syndrome is a term given to a constellation of comorbidities
manifested within a single individual and owing to the initiating condition of obesity. The
term itself has been in common, though poorly defined, usage as early as the 1950s.
The first appearance of the term “metabolic syndrome” in a peer reviewed journal
indexed by PUBMED was by an Israeli group in 1972 (11). Though they were the only
group to publish a manuscript employing the term metabolic syndrome in that year, by
1977, the term began to be used annually in a limited number of publications and it was
in the early 1990s that the study of metabolic syndrome became mainstream with
publication numbers rising from two in 1990 to 113 in 1999 with the trend continuing to a
startling 3734 publications containing the term metabolic syndrome in 2010 (See Figure
1).
This impressive growth in metabolic syndrome research directly parallels the
growth in numbers of obese individuals here in the United States and abroad.
According to the National Health and Nutrition Examination Surveys, approximately
33.8% of Americans are obese (BMI >30) with a nearly equivalent percentage meeting
the criteria for overweight (BMI >25) (4). Sampling back to 1960 demonstrates a near
exponential rise in the number of obese individuals starting in 1980 and continuing to
the turn of the century (See Figure 2) (15).

Fortunately it appears that this

phenomenonal growth in obesity is beginning to plateau, though extensive speculation
exists attributing the plateau to ever diminishing numbers of individuals whose BMI falls
below 25 remaining to enter into overweight or obese categories. It is worth noting that
while some regionality does exist with regards to the BMI of an average citizen, when
examined by state it becomes apparent that there are no startlingly obese states
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causing a shift in the statistics as the current distribution ranges from 21% in Colorado
to 34% in Mississippi (1). This trend in obesity shows no evidence of significant future
abatement as approximately 17% of children age 2-19 are already obese (14). It is in
this overweight and obese population of children, adolescents and adults that you will
find those individuals with the predisposing characteristics for development of metabolic
syndrome and it is because of the high prevalence of obesity that approximately 34% of
all adult Americans met the diagnostic criteria for metabolic syndrome in 2006 (3).
A problem that metabolic syndrome research has suffered for a number of years
is an unsatisfactory definition for the diagnostic criteria of the syndrome itself. The
combination in increase of incidence/prevalence of metabolic syndrome paired with the
drastic increase in metabolic syndrome directed research efforts globally led the
American Heart Association to set guidelines for the definition of metabolic syndrome in
the National Cholesterol Education Program’s Adult Treatment Panel III report in 2004
(9).

In this panel, six key components of metabolic syndrome were identified:

abdominal obesity, atherogenic dyslipidemia, hypertension, a proinflammatory state, a
prothrombotic state and insulin resistance with or without glucose intolerance. It was
further stated that abdominal obesity, clinically presented as increased waist
circumference, was both the strongest predictor of metabolic syndrome as well as a key
contributor to all other identified comorbidities (9). To meet the diagnostic criteria of
metabolic syndrome, a single individual must present with a minimum of three of the
above listed pathologies (9).
The metabolic syndrome can be thought of in lay-terms as an increase in the
chance of a negative outcome subsequent to a cardiovascular event. This is due to the
3

multifaceted complications that the metabolic syndrome presents to the vasculature
itself (13). Highlighted vascular deficits included within the syndrome are: increased
vascular tone, increased incidence of atheroma formation, increased incidence of
thrombus formation, endothelial dysfunction, vascular wall remodeling, and vascular
network remodeling (6; 13).

The outcome of this integrated vascular system

dysfunction with the greatest impact on quality of life is peripheral vascular disease,
wherein perfusion cannot be appropriately regulated to match changes in metabolic
demand (2; 5). This results in an obese individual who becomes obese as a result of an
imbalance in caloric homeostasis and ultimately remains obese due to an inability in
peripheral skeletal tissues to adequately supply blood flow to reverse this imbalance (5;
6).

In other words, people go from being obese because of a lack of appropriate

exercise to meet their caloric intake to being unable to increase their caloric
consumption by skeletal muscle due to inadequate perfusion.
The work detailed within this document investigates the role of metabolic
syndrome induced alterations in cyclooxygenase mediated arachidonic acid metabolism
in skeletal muscle microvascular disease. Initial investigations will demonstrate the role
of these alterations in vasomotor dysfunction in animal models of metabolic syndrome
but which ultimately serve as the foundational work for the investigation into the role of
this shift in the progressive loss of microvessel density (rarefaction) demonstrated within
the syndrome.

By the conclusion of this document, it is the author’s intention to

demonstrate a significant role for the shift in arachidonic metabolism in causing
microvascular rarefaction and identify prospective, potentially clinically relevant targets
for intervention meriting future investigation.

4

Endothelial Dysfunction
Endothelial dysfunction is generically a loss of normal physiologic function in the
vascular endothelium with regards to barrier, anti-thrombotic character, regulatory,
vasomotor, etc (18; 20; 23). Of particular relevance to the metabolic syndrome are the
vasomotor consequences of endothelial dysfunction which can be defined as a
diminished responsiveness of the vascular endothelium to vasodilator stimuli (primarily
mediated through NO and prostacyclin; collectively termed endothelial derived relaxing
factors) along with exaggerated responses to constrictor stimuli (6).

This is a major

cause of disparities in demand:perfusion matching in the peripheral tissues in metabolic
syndrome subjects.

In addition to being a hallmark of the metabolic syndrome,

endothelial dysfunction is one of the most extensively studied vasculopathies today.
Particular attention is paid to the role of endothelial nitric oxide synthase (eNOS) in the
endothelial dysfunction literature.
As previously stated, endothelial dysfunction is defined, in part, by a diminished
responsiveness of the vasculature to endothelium dependent vasodilator stimuli. The
mechanisms by which these impairments can occur are varied and not mutually
exclusive.
(EDRF),

They include scavenging of the endothelium derived relaxing factors
diminished

production

of

the

EDRF,

functional

antagonism

by

a

vasoconstrictive force, inability of the EDRF to reach the effector sites and decreased
responsiveness of the vascular smooth muscle to the EDRF. Numerous studies have
demonstrated that individuals and experimental animals with metabolic syndrome suffer
from endothelial dysfunction (5; 17). Many of these studies have further demonstrated
the role of ROS in the etiology of endothelial dysfunction in metabolic syndrome
5

subjects with additional studies demonstrating the therapeutic potential of antioxidants
in treatment of the dysfunction (21; 25) as well obesity associated acute myocardial
infarctions (12). Since a major portion of this manuscript deals with the alterations in
arachidonic acid metabolite balance, prostacyclin will be discussed in subsequent
sections whereas a brief overview of eNOS and NO is detailed below.
The primary function of eNOS is the conversion of L-arginine to L-citrulline,
resulting in the release of the potent vasodilator, nitric oxide (NO), as a reaction side
product. While this role is well established, more recent studies of vascular pathologies
have also had cause to focus on a phenomenon termed eNOS uncoupling. In eNOS
uncoupling,

limiting

concentrations

of

either

L-arginine

or

the

cofactor

tetrahydrobiopterin (BH4) cause eNOS to demonstrate a NADPH oxidase-like activity
resulting in the production of O2- (16). Depletion of BH4 does not necessarily stem from
a metabolic inadequacy in all cases. Studies have demonstrated that peroxynitrite can
oxidize the essential cofactor for eNOS activity, tetrahydrobiopterin (BH4) thereby
uncoupling eNOS (24). In a sense this is a feedback loop as peroxynitrite is the product
of the interaction between superoxide and NO. Therefore, with a modest increase in
global oxidant stress comes the potential for a positive feedback loop wherein a small
production of peroxynitrite can in turn scavenge BH4, thereby uncoupling eNOS
resulting in the production of superoxide which could in turn interact to produce
additional peroxynitrite and so on. This serves as a mechanism by which global oxidant
stress can not only increase ROS production through secondary pathways but also
attenuate the production of normal vaso-regulatory compounds.
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Additionally, since peroxynitrite is generated by the interaction of O2- with NO, as
previously discussed, the effect on the systemic vasculature is exaggerated by both
scavenging the existing NO and altering the catalytic activity of eNOS blocking further
NO production.

Peroxynitrite is not, however, alone in its ability to crosstalk and

uncouple eNOS. Angiostatin, high glucose, ceramide, homocysteine and hypochlorous
acid have all been shown to promote uncoupling in cultured endothelial cells.
Microvascular Rarefaction
Generically, rarefaction is a term defining any process wherein your subject or
target of interest becomes less prevalent. In the case of microvascular rarefaction, this
means that the arterioles and capillaries within a tissue of interest are becoming less
prevalent when compared between conditions. The metabolic syndrome, demonstrates
the process of microvessel rarefaction in skeletal muscle tissues when comparing
between comparable lean and obese animals or humans. The consequence of this
rarefactive process is the inability to match tissue demand and perfusion even in
maximally dilated vascular beds. This was clearly demonstrated in 2003 in work by
Frisbee et al. showing that the consequence of significant rarefaction is a true structural
inability to match demand and perfusion resulting in a disparity with no short term
temporal solution.
While the fact of rarefaction is established, the mechanisms of rarefaction have
classically been poorly understood.

In metabolic syndrome, rarefaction has been

attributed to hypertension, dyslipidemia, insulin sensitivity, and vascular NO
bioavailability. Using a technique first pioneered by Greene et al., (8) we are able to
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examine skeletal muscle microvessel density in animal models of metabolic syndrome
rapidly and with high resolution. In this document, we will demonstrate that the process
of rarefaction is a multi-mechanistic continuum of problems resulting in diminished
tissue capillarity in the skeletal muscle of metabolic syndrome animal models.
Arachidonic Acid Metabolism
Arachidonic acid (AA) is stored in the membranes of nearly all known mammalian
cells bound to membrane phospholipids. It can be released from this stored state by
the actions of phospholipase A, phospholipase C or phospholipase D.

As

phospholipase A is capable of releasing AA in a single step as opposed to the multistep
processes of phospholipases C & D, it is generally the focus of the most research
attentions.

Subsequent to phospholipase mediated release from the plasma

membrane, free vascular AA has 3 basic fates. It can be reincorporated into the plasma
membrane bound once again to membrane phospholipids, it can diffuse away in the
bloodstream to distal locations or it can diffuse into the cytoplasmic space of the cell. If
AA diffuses into the cytoplasm, it is enzymatically degraded down one of three major
enzymatic pathways: the cyclooxygenase pathway (COX), the lipoxygenase pathway
(LOX) or the cytochrome P450 pathway (CYP450).
The cyclooxygenase pathway is the major enzymatic producer of a class of
compounds known as prostanoids. These metabolic end-products of AA metabolism
are the result of the activity of cyclooxygenase converting AA into prostaglandin H2.
Prostaglandin H2 itself serves as the precursor to all series 2 prostanoids including
prostacyclins, thromboxanes and prostaglandins. While all 3 categories of series 2
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prostanoids have been shown to produce numerous biological effects, prostacyclin and
thromboxane generally receive the greatest attention in the cardiovascular literature as
there is extensive evidence indicating both classes of compounds are key regulators of
vasomotor tone in specific physiologic and pathophysiologic conditions. Classically
these vascular considerations of thromboxane and prostacyclin are limited to the
vasomotor as they are a potent vasoconstrictor and vasodilator, respectively.
Alternative to the cyclooxygenase pathway is the 5, 12, 15 lipoxygenase
pathway.

This family of enzymes is responsible for catalyzing the conversion of

arachidonic acid into a family of compounds collectively referred to as the leukotrienes.
Leukotrienes are not considered to be major regulators of vascular tone as their effects
are more relevant in the mediation of immune responses. Leukotriene A4 in particular
has been implicated strongly in allergic asthma though its effects are not unique to that
condition.

Neutrophil recruitment, direct tracheal smooth muscle contraction,

sustainment of inflammatory responses and acute allergic actions have all been
attributed to leukotriene dependent processes.
The final pathway for the enzymatic metabolism of arachidonic acid is the CYP
450 pathway. This pathway can be broken into two subcategories: the epoxygenase
pathway and the ω-hydroxylase pathway. While both pathways are controlled by the
activity of p-type-cytochromes and act on the same precursor, the epoxygenase
pathway generates a class of compounds known as epoxyeicostreienoic acids (EETs)
while

the

ω-hydroxylase

pathway

is

responsible

for

the

production

of

hydroxyeicosatetraenoic acid (HETES). While roles for both classes of compounds
have been indicated in the regulation of vascular tone, as well as roles in inflammation
9

and oxidative stress, the studies contained herein failed to establish a role for CYP450
metabolites of AA and as such further discussion of these pathways will not be included.
Alterations in AA metabolism can have direct effects on vasomotor function.
Increases in vascular oxidant stress can lead to shifts in the metabolism of AA through
the COX pathway independent of the direct effects of ROS on prostacyclin synthase.
Studies performed in the obese Zucker rat demonstrate that with changes to vascular
oxidant stress, comes a shift in the metabolism of arachidonic acid through the COX
pathway from a predominant production of prostacyclin to a predominant production of
thromboxane (TXA2) in response to hypoxia (7). The net effect of this shift is a blunted
vasodilation in response to a highly specific vasodilator stimulus. This finding has been
supported by additional studies which have demonstrated increased production of the
vasoconstrictors PGH2 (19), PGF2α (22) and TXA2 (10) along with diminished
prostacyclin production in the diabetic experimental animals. This shift in arachidonic
acid metabolism to the generation of greater production of vasoconstrictor stimuli serves
to blunt the response of the endothelium to vasodilator stimuli as the vasodilator
functions are masked by the tonic vasoconstrictive forces. While these effects have
been documented within the literature, this manuscript will set out to establish a role for
alterations in AA metabolism which stretch beyond the vasomotor and show
demonstrable, significant, deleterious effects on vascular network structure.
Conceptual Framework for Subsequent Chapters
Due to the fact that the majority of remaining chapters in this document were
originally intended as stand-alone texts, the logic linking each chapter to its predecessor
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and successor may not be immediately apparent.

As such, we present here a

conceptual framework in which to consider each manuscript contained within this body
of work as a part of a greater intellectual approach to the study of vascular
consequences of metabolic syndrome and the roles of arachidonic acid metabolites in
these pathophysiologic processes. Chapter 2 of this document is entitled “Increased
Vascular Thromboxane Generation Impairs Dilation of Skeletal Muscle Arterioles of
Obese Zucker Rats with Reduced Oxygen Tension.” This chapter is the foundational
work upon which the author has continued his experimental designs through the course
of his graduate education. It makes the initial observation that when a highly specific
stimulus for vascular prostacyclin production, hypoxia, is employed in both lean and
obese Zucker rats, there is a blunted dilation with obesity that is mediated exclusively by
a shift from a predominant production of prostacyclin to a blunted prostacyclin and
exaggerated thromboxane generation response.

Additionally, this chapter provides

some of the initial experiments indicating a role for elevations in oxidant stress as
mediators for elevations in thromboxane generation.
Chapter 3 of this document is entitled “Increased Arachidonic Acid-Induced
Thromboxane Generation Impairs Skeletal Muscle Arteriolar Dilation with Genetic
Dyslipidemia. In this chapter, we leave the obese Zucker rat model and instead focus
on two genetic variants of the C57/Bl/6J mouse with specific gene deletions of either the
low density lipoprotein receptor or the apolipoprotein E gene resulting in an animal
model of familial hypercholesterolemia or type III hyperlipidemia respectively. In this
study we demonstrate that in an animal model of hypercholesterolemia, a comorobidity
of metabolic syndrome, AA metabolism shifts in a directionally consistent manner with
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the more complex disease state of metabolic syndrome. Additionally, this manuscript
provides further evidence for elevations in ROS as a mediator of the shift in AA
metabolites.
Chapter 4 of this manuscript is titled “Impact of Chronic Anticholesterol Therapy
on Development of Microvascular Rarefaction in the Metabolic Syndrome.”

This

chapter returns to the obese Zucker rat model investigating how statin and fibrate
therapies affect progression of skeletal muscle microvascular rarefaction in the
metabolic syndrome. This paper, interestingly, demonstrates that protective effects of
statin therapies can be conferred with regards to rarefaction, however, these effects are
independent of plasma cholesterol levels and seem to be mediated by the pleiotropic
effects in diminishing oxidative stress and inflammatory status. This paper serves a
critical role in further demonstrating that microvascular rarefaction in fully developed
metabolic syndrome animal models strongly correlates with diminished vascular NO
bioavailability and that protection against microvessel loss is only conferred by those
therapeutics capable of protecting against the loss of NO bioavailability.
The culmination of these ongoing investigations into metabolic syndrome related
microvascular rarefaction is presented in Chapter 5 entitled, “Temporal Progression of
Microvascular Rarefaction in the Metabolic Syndrome; The Role of Thromboxane A2.”
This incomplete work shows the preliminary investigations into a higher resolution,
temporal analysis of the process of rarefaction in metabolic syndrome.

It clearly

demonstrates a biphasic rarefactive process mediated in the early phase by elevations
in thromboxane A2 levels and in the later phase by diminished vascular NO
bioavailability. This chapter provides the evidence that the early alterations to COX
12

mediated AA metabolism have effects that extend beyond the vasomotor with significant
impact

on

vascular

network

structure

through

the

life

of

the

animal.

Supplementary materials which may provide a greater appreciation for the work
presented

within

this

manuscript

include

“Differential

Impact

of

Familial

Hypercholesterolemia and Combined Hyperlipidemia on Vascular Wall and Network
Remodeling in Mice” by Stapleton et al. which provides some of the foundational
correlative data between elevation in TxA2 production and changes to vascular wall
mechanics in hyperlipidemic mice. Additional insight into the significance of this work
can be found in the article entitled “Aspirin Resistance with Genetic Dyslipidemia:
Contribution of Vascular Thromboxane Generation” by Frisbee et al. which was also
performed in dyslipidemic mice and highlights why inhibition of COX is a poor
therapeutic target in an animal model with a single metabolic syndrome comorbidity and
helps to better explain why our investigations into metabolic syndrome related skeletal
muscle microvascular rarefaction employ more selective inhibition of enzymes
downstream from COX as opposed to general COX inhibition which may be more
clinically employed though, plausibly, less therapeutically relevant.
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FIGURE LEGENDS
Figure 1.

This figure legend is directly taken, as is the figure from the associated

citation: Age adjusted by the direct method to the year 2000 U.S. Census Bureau
estimates, using the age groups 20-39, 40-59, and 60-74 years. Pregnant females
were excluded. Overweight is defined as a body mass index (BMI) of 25 or greater but
less than 30; obesity is a BMI greater than or equal to 30; extreme obesity is a BMI
greater than or equal to 40. Source: CDC/NCHS, National Health Examination Survey
cycle 1 (1960-1962); National Health and Nutrition Examination Survey (1971-1974), II
(1976-1980), and III (1988-1994), 1999-2000, 2001-2002, 2003-2004, 2005-2006, and
2007-2008. (15)

Figure 2.

Annual usage of the term “metabolic syndrome” as determined by an

independent search of PUBMED.
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CHAPTER 2

INCREASED VASCULAR THROMBOXANE GENERATION IMPAIRS DILATION OF
SKELETAL MUSCLE ARTERIOLES OF OBESE ZUCKER RATS WITH REDUCED
OXYGEN TENSION

Adam G. Goodwill, Milinda E. James and Jefferson C. Frisbee
Center for Interdisciplinary Research in Cardiovascular Sciences
Department of Physiology and Pharmacology
West Virginia University School of Medicine, Morgantown, WV 26506

Running Head: Vasodilation and metabolic syndrome

"This research was originally published in The American Journal of Physiology Heart & Circulatory
Physiology. Goodwill AG, James ME, Frisbee JC . Increased vascular thromboxane generation impairs
dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension. Am J Physiol
Heart Circ Physiol. 2008 Oct;295(4):H1522-8. “
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ABSTRACT
This study determined if altered vascular prostacyclin (PGI2) and/or thromboxane (TxA2)
production with reduced PO2 contributes to impaired hypoxic dilation of skeletal muscle
resistance arterioles of obese Zucker rats (OZR) vs. lean Zucker rats (LZR).
Mechanical responses were assessed in isolated gracilis muscle arterioles following
reductions in PO2 under control conditions and following pharmacological interventions
inhibiting arachidonic acid metabolism, nitric oxide synthase, and alleviating elevated
vascular oxidant stress. Production of arachidonic acid metabolites was assessed using
pooled arteries from OZR and LZR in response to reduced PO2.

Hypoxic dilation,

endothelium-dependent in both strains, was attenuated in OZR vs. LZR. NOS inhibition
had no significant impact on hypoxic dilation in either strain. COX inhibition dramatically
reduced hypoxic dilation in LZR and abolished responses in OZR. Treating arterioles
from OZR with PEG-SOD improved hypoxic dilation, and this improvement was entirely
COX-dependent. Vascular PGI2 production with reduced oxygen tension was similar
between strains, although TxA2 production was increased in OZR; a difference that was
attenuated by treatment of vessels from OZR with PEG-SOD.

Both blockade of

PGH2/TxA2 receptors and inhibition of thromboxane synthase increased hypoxic dilation
in OZR arterioles. These results suggest that a contributing mechanism underlying
impaired hypoxic dilation of skeletal muscle arterioles of OZR may be an increased
vascular production of TxA2, which competes against the vasodilator influences of PGI2.
These results also suggest that the elevated vascular oxidant stress inherent in the
metabolic syndrome may contribute to the increased vascular TxA2 production and may
blunt vascular sensitivity to PGI2.
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Key Words: skeletal muscle microcirculation, endothelium-dependent dilation, vascular
reactivity, rodent models of obesity
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INTRODUCTION
The metabolic syndrome represents a series of systemic pathologies that develop
sequentially in afflicted individuals, and can include obesity, insulin resistance/type II
diabetes mellitus, dyslipidemia and hypertension (25). While each of these pathologies in
isolation can increase the future risk for development of peripheral vascular disease, when
present in combination this risk increases dramatically (24), and can lead to numerous
profound alterations to vascular structure/function relationships (26, 27). These vascular
alterations can impair to tissue perfusion:demand matching and can lead to a
compromised function (27). An effective animal model for the metabolic syndrome in
humans is the obese Zucker rat (OZR), a rodent model characterized by its dysfunctional
leptin receptor gene, resulting in abrogated leptin signaling and an impaired satiety reflex
(10). As a result, the OZR experiences a chronic hyperphagia, and sequentially develops
each of the systemic pathologies listed above, in addition to both pro-oxidant and proinflammatory states (1, 6, 22). Previous studies by multiple investigative groups have
demonstrated negative vascular outcomes in OZR with development of the metabolic
syndrome, including alterations to vascular wall mechanics (4, 13, 28, 29), impairments to
multiple indices of dilator reactivity (9, 13, 15, 16, 33), signaling mechanisms underlying
constrictor reactivity (17, 21, 30) and a rarefaction of microvascular networks within multiple
tissues (7, 8, 31). The culmination of these alterations to microvascular structure and
function within OZR can result in profound impairments to the perfusion of tissue under an
array of physiological and pathological conditions (8, 12, 33).
We have previously demonstrated that the dilator reactivity of skeletal muscle
resistance arterioles in response to an acute reduction in oxygen tension is impaired in
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OZR compared to LZR, and that a contributing mechanism to this impairment lies within
the chronic elevation in vascular oxidant stress (9). However, while this previous study did
not implicate specific mechanisms beyond the contribution of elevated vascular oxidant
stress, recent studies from Hester’s group have provided data which may have
considerable bearing on not only our previous observation, but also on the integrated
regulation of vascular reactivity in the skeletal muscle of OZR (32, 33). Specifically, the
dilator response of in situ spinotrapezius muscle arterioles with increased metabolic
demand, previously determined to be a largely dependent on vascular production of
prostacyclin (PGI2, Ref. 11), was blunted in OZR compared to LZR. This observation may
reflect an enhanced vascular production of thromboxane A2 (TxA2), or elevated
vasoconstrictor response to TxA2 within OZR that is not present in lean animals (32, 33).
Clearly, any increase in TxA2 production has the potential to compete against PGI2mediated responses and impair dilator reactivity to multiple vasoactive stimuli.
The purpose of the present study was to more fully elucidate mechanisms
contributing to the impaired dilation of skeletal muscle arterioles of OZR in response to
reduced PO2. Additionally, the present study was designed to more clearly determine the
role for elevated vascular oxidant stress in contributing to the attenuated hypoxic dilation of
arterioles from OZR. Specifically, the hypothesis tested by the present experiments was
that the compromised dilator reactivity of skeletal muscle arterioles of OZR in response to
reduced PO2 compared to responses in LZR is due to a reduction in the vascular
production of PGI2 and an increased vascular production of TxA2 as a result of the acute
reductions in oxygen tension. Further, these effects on PGI2 and TxA2 production will be
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the result of an elevation in vascular oxidant stress, altering arachidonic acid metabolism
within arterioles of OZR.

MATERIALS AND METHODS
Animals: 15-17 week old male lean and obese Zucker rats (LZR and OZR, respectively)
were used for all experiments. Rats were fed standard chow and tap water ad libitum, and
all protocols received prior IACUC approval.

After an overnight fast, rats were

anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal
intubation to facilitate maintenance of a patent airway. In all rats, a carotid artery and an
external jugular vein were cannulated for determination of arterial pressure and for
intravenous infusion of supplemental anesthetic, if necessary. While under anesthetic, an
aliquot of blood was drawn from the jugular vein to be used for the biochemical
determination of plasma glucose (Freestyle; Abbott Diabetes Care, Alameda, CA), insulin
(Linco; St. Charles, MO), and nitrotyrosine concentrations (Linco; St. Charles, MO) as well
as a plasma lipid profile (Stanbio; Boerne, TX) from each animal.
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized rats,
the intramuscular continuation of the gracilis artery was identified and surgically
removed. Arterioles were placed in a heated chamber (37°C) that allowed the vessel
lumen and exterior to be perfused and superfused, respectively, with physiological salt
solution (PSS; equilibrated with 21% O2, 5% CO2; 74% N2) from separate reservoirs.
Vessels were cannulated at both ends and were secured to inflow and outflow glass
micropipettes connected to a reservoir perfusion system allowing intralumenal pressure
and gas concentrations to be controlled. Arterioles were extended to their in situ length
and were equilibrated at 80% of the animal's mean arterial pressure (Table 1). Vessel
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diameter was measured using television microscopy and an on-screen video
micrometer, and all mechanical responses of arterioles were assessed under
pressurized conditions with no flow through the arteriolar lumen.
Subsequent to the initial equilibration period, the reactivity of isolated arterioles
was assessed following challenge with reduced PO2 (ΔPO2 from ~135 mmHg [21% O2]
– ~45 mmHg [0% O2]) under an array of physiological and pharmacological conditions
(described below). In an additional series of experiments, isolated arterioles were also
challenged with increasing concentrations of the selective thromboxane A2 mimetic U46619 (10-12 M – 10-8 M; Biomol) and prostacyclin (PGI2•Na; 10-12 M – 10-8 M; Biomol) to
determine the intrinsic sensitivity of microvessels to these stimuli.
Removal of the arteriolar endothelium was accomplished by passing an air bolus
through the perfusate line into the isolated microvessel, the efficacy of which was
determined from a loss of all dilator reactivity in response to application of 10-6 M
acetylcholine. To assess the contribution of nitric oxide production or the generation of
metabolites via cyclooxygenase as mediators of arteriolar reactivity, isolated vessels
were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (LNAME; 10-4 M; Sigma) or the cyclooxygenase inhibitor indomethacin (INDO; 10-5 M;
Sigma), respectively.

To antagonize vascular PGH2/TxA2 receptors, vessels were

treated with SQ-29548 (10-5 M; Biomol), while inhibition of thromboxane synthase was
accomplished using carboxyheptyl imidazole (CHI; 10-5 M; Biomol). To reduce vascular
oxidant stress, arterioles were treated with polyethylene glycol-superoxide dismutase
(PEG-SOD; 200 U/ml; Sigma).
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Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6keto-prostaglandin F1α (6-keto-PGF1α; the stable breakdown product of PGI2; Refs. 18, 23),
and 11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product
of TxA2; Ref. 5) in response to challenge with reduced oxygen tension was assessed using
pooled conduit arteries (femoral, saphenous, iliac) from LZR and OZR. Pooled vessels
from each animal were incubated in microcentrifuge tubes in 1 ml of physiological salt
solution for 30 minutes under control conditions (21% O2). After this time, the superfusate
was removed, stored in a new microcentrifuge tube and frozen in liquid N2, while a new
aliquot of PSS was added to the vessels and the equilibration gas was switched to 0% O2
for the subsequent 30 minutes. After the second 30 minute period, this new PSS was
transferred to a fresh tube, frozen in liquid N2 and stored at -80°C. Metabolite release by
the vessels was determined using commercially available EIA kits for 6-keto-PGF1α and 11dehydro-TxB2 (Cayman).
Data and Statistical Analyses: Active tone of individual arterioles at the equilibration
pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest
in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the
equilibration pressure in Ca2+-free PSS.
Mechanical responses of isolated arterioles following challenge with increasing
concentrations of thromboxane or prostacyclin were fit with the three-parameter logistic
equation:

⎡ max − min ⎤
y = min + ⎢
log EC50 − x ⎥
⎣1 + 10
⎦
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where y represents the change in arteriolar diameter, “min” and “max” represent the
minimum and maximum bounds, respectively, of the change in arteriolar diameter with
increasing agonist concentration, x is the logarithm of the agonist concentration and

log EC 50 represents the logarithm of the agonist concentration ( x ) at which the response
( y ) is halfway between the minimum and maximum bounds.
Data are presented as mean±SEM.

Statistically significant differences in the

magnitude of hypoxic dilation, vascular production of 6-keto-PGF1α and 11-dehydro-TxB2,
and the calculated parameters describing the thromboxane or prostacyclin concentrationresponse relationships were determined using analysis of variance (ANOVA). In all cases,
Student-Newman-Keuls post hoc test was used when appropriate and p<0.05 was taken to
reflect statistical significance.

RESULTS
Table 1 presents baseline characteristics of LZR and OZR in the present study. At
15-17 weeks of age, OZR demonstrated profound obesity, severe insulin resistance, and
dyslipidemia

characterized

hypertriglyceridemia.

by

moderate

hypercholesterolemia

and

severe

In addition, OZR also presented a moderate elevation in mean

arterial pressure as compared to LZR. Plasma levels of nitrotyrosine, a protein marker of
chronic elevations in oxidant stress, were significantly elevated in OZR compared to LZR.
With regard to basal vascular tone, isolated arterioles from both rat strains demonstrated a
comparable resting active diameter, although passive diameter was reduced in OZR
versus LZR. However, this remodeling of the vessel wall did not translate into a difference
in calculated active tone between the strains.
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Data summarizing hypoxic dilation of resistance arterioles from LZR and OZR are
presented in Figure 1. As shown in Panel A, arterioles from OZR exhibited a blunted
dilator response to reduced PO2 compared to vessels from LZR. However, arteriolar
reactivity to reduced oxygen tension was abolished in both groups following removal of the
vascular endothelium. Panel B presents data describing the contribution of nitric oxide
synthase (NOS) and cyclooxygenase (COX) products to arteriolar dilation in response to
reduced PO2 in LZR and OZR. While NOS inhibition has a consistently minor, albeit
statistically insignificant, blunting of hypoxic dilation in arterioles of LZR, treatment of
vessels with L-NAME had no discernible impact on this response in OZR. In contrast,
incubation of vessels with indomethacin dramatically reduced hypoxic dilation in arterioles
from both strains.

Combined treatment with L-NAME and indomethacin abolished all

vascular responses to reduced PO2 in both LZR and OZR. Panel C presents the impact of
pre-treatment of arterioles with the anti-oxidant PEG-SOD on both the magnitude of
hypoxic dilation in these vessels and on the contributions from NOS and COX. Treatment
of vessels with PEG-SOD had no significant impact on either the magnitude of hypoxic
dilation or on the contribution of NOS and COX products to this response in LZR. In
contrast, following incubation with PEG-SOD, arterioles from OZR exhibited an improved
dilation in response to reduced PO2, and this enhanced reactivity was entirely dependent
on COX metabolism.
Figure 2 presents data describing the production of 6-keto-PGF1α (the stable
breakdown product of PGI2) and 11-dehydro-TxB2 (the stable breakdown product of TxA2)
from pooled vessels of LZR and OZR in response to reduced PO2. As shown in Panel A,
vessels from both LZR and OZR demonstrated a significant increase in 6-keto-PGF1α
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production in response to reduced PO2, although this increase was greater in LZR as
compared to OZR. In both cases, treatment of vessels with indomethacin abolished 6keto-PGF1α production in response to reduced oxygen tension. With regard to the vascular
production of TxA2, vessels from both LZR and OZR exhibited a significant increase in 11dehydro-TxB2 production following exposure to reduced PO2, although this level of
production was dramatically elevated in vessels from OZR (Panel B). In both cases,
production of 11-dehydro-TxB2 was abolished following treatment of vessels with either
indomethacin or CHI, suggesting that all production of TxA2 was mediated via the actions
of thromboxane synthase distal to COX.
Data describing the production of 6-keto-PGF1α and 11-dehydro-TxB2 in response to
reduced PO2 in vessels from OZR subsequent to pre-treatment with PEG-SOD are
summarized in Figure 3.

Treatment of vessels with PEG-SOD did not alter 6-keto-

PGF1α production in vessels from OZR compared to levels in untreated vessels (Panel A).
However, as compared to levels determined in untreated vessels, incubation of arteries
from OZR with PEG-SOD blunted the enhanced production of 11-dehydro-TxB2 (Panel B)
Treatment of vessels with indomethacin abolished reduced PO2-induced production of 6keto-PGF1α and 11-dehydro-TxB2.
Figure 4 presents data summarizing the dilator responses of arterioles from LZR
and OZR in response to reduced PO2 following antagonism of either the PGH2/TxA2
receptor with SQ-29548 or thromboxane synthase with CHI.

While neither of these

pharmacological interventions had a consistent and significant impact on response in
vessels from LZR, both SQ-29548 and CHI significantly increased hypoxic dilation in
arterioles from OZR.
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Arteriolar reactivity in response to challenge with increasing concentrations of
thromboxane or prostacyclin is summarized in Figure 5. Arteriolar constriction in response
to increasing concentrations of thromboxane was not different between LZR and OZR, and
neither EC50 nor maximum bound were impacted in response to pre-treatment of the
vessels with PEG-SOD (Panel A). Further, arteriolar responses to thromboxane were
abolished in vessels from both animal strains following incubation of the vessels with SQ29548 (Panel B). With increasing concentrations of prostacyclin, arterioles from OZR
exhibited a blunted dilator response compared to that determined in arterioles from LZR,
and treatment of vessels with PEG-SOD significantly improved dilator reactivity to
prostacyclin, although not to the level determined in LZR (Panel C).

EC50 was not

significantly different between groups with regard to vascular reactivity in response to
increasing concentrations of PGI2 (data not shown)

DISCUSSION
Inherent within the development of the multi-pathology state that defines the
metabolic syndrome is an array of alterations to vascular and microvascular structure and
function that have the potential to profoundly impact the perfusion of tissues and organs, as
well as the contributing mechanisms which comprise this integrated process. Previous
studies have clearly demonstrated that alterations to the patterns of vasodilator (8, 12) and
vasoconstrictor (30) reactivity, as well as vessel wall remodeling (28, 29) and a reduction in
microvessel density (7) all represent avenues through which vascular function and tissue
perfusion can be compromised. The purpose of the present study was to build on our
previous observation of an impaired dilation of skeletal muscle resistance arterioles of OZR
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in response to acute reductions in oxygen tension, and the possible contributing role of
elevated vascular oxidant stress in this process (9).
Comparable to our observations in the first study, hypoxic dilation of skeletal muscle
resistance arterioles from OZR was significantly reduced compared to that determined in
LZR (Figure 1, Panel A). While this response was abolished following removal of the
endothelium in both rat strains, comparable to the complete endothelium-dependence of
hypoxic dilation in other rodent models (14, 19, 20), our results also support previous
observations of a strong dependence on COX products in mediating hypoxic dilation of
these vessels (18-20).

Interestingly, in our initial study we determined a small, but

significant role for NOS activity in mediating hypoxic dilation in arterioles from LZR. In the
present study this effect was not statistically significant, suggesting that it may represent a
minor contributor to arteriolar dilation in response to reduced oxygen tension in LZR.
However, while the magnitude of this response is relatively minor in LZR, both the results
from the present study and our previous one (9) indicate that this is completely lost with the
development of the metabolic syndrome in OZR. Additionally, pre-treatment of arterioles
from OZR with the oxidative free radical scavenger PEG-SOD to lower the elevated
oxidant stress in these animals resulted in a significant improvement to hypoxic dilation in
the obese rats (Figure 1, Panel C). This improvement to hypoxic dilation was confined to
activity involving COX only, as treatment with indomethacin abolished hypoxic dilation in
OZR, and treatment with L-NAME was without effect.
Recent studies from Hester’s group suggest that functional dilation (i.e., arteriolar
dilation in response to elevated metabolic demand) is impaired in OZR as a result of
alterations to arachidonic acid metabolism which can result in activation of thromboxane
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receptors causing a competing constrictor influence which acts to partially constrain dilator
responses (32, 33). Given that both functional dilation for in situ spintotrapezius muscle of
LZR (11) and hypoxic dilation of skeletal muscle arterioles of LZR (9) has previously been
shown to be strongly dependent on the vascular production of PGI2, we sought to
determine if an alteration in arachidonic acid metabolism, resulting in an increased vascular
production of thromboxane or a decreased production of prostacyclin may contribute to this
impaired reactivity in arterioles of OZR.

As shown in Figure 2, arteries from OZR

exhibited a significant increase in the production of PGI2 (estimated from measurements of
6-keto-PGF1α) in response to reductions in oxygen tension. While this was not as robust a
response as that determined for arteries of LZR, it is unclear if this degree of attenuation in
PGI2 production in OZR is sufficient to manifest itself as a blunted mechanical response. In
contrast, vascular production of TxA2 (estimated from measurements of 11-dehydro-TxB2),
mildly elevated in arteries of LZR during reduced oxygen tension, was dramatically
increased in vessels from OZR following exposure to reduced PO2.

Finally, while

treatment of arteries from both strains with indomethacin abolished production of PGI2 and
TxA2 in response to reduced oxygen tension, the treatment of vessels of OZR with CHI, an
inhibitor of thromboxane synthase, severely reduced thromboxane production in vessels
from OZR (Figure 2, Panel B).

These results suggest that reduced PO2 causes an

increased production of TxA2 from vessels of OZR, mediated via thromboxane synthase,
and that this may compete with the dilator influences of vascular production of PGI2.
However, it should be emphasized that these results must be interpreted cautiously, as the
production of metabolites of arachidonic acid was assessed using conduit arteries and not
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resistance arterioles, while the reverse is true with regard to the study of the mechanical
responses.
In order to better understand the impact of elevated vascular oxidant stress on the
impaired dilator responses to reduced PO2 in vessels of OZR, we treated vessels with
PEG-SOD prior to exposure to reduced PO2 and determined the levels of 6-keto-PGF1α
and 11-dehydro-TxB2 in the incubation superfusate (Figure 3). These data suggest that
while oxidant stress does not play a significant role in any reduction in the vascular
production of prostacyclin (as the addition of PEG-SOD was without effect), elevated
vascular oxidant stress may contribute to the increased production of thromboxane by
these vessels, as incubation with the anti-oxidant significantly reduced the levels of 11dehydro-TxB2 in the superfusate. However, this effect was not complete, as the levels of
11-dehydro-TxB2 production remained elevated in the superfusate despite the presence of
PEG-SOD, indicating that additional factors may contribute to thromboxane production in
vessels of OZR which are independent of the effects of acute reduction in vascular oxidant
stress. This observation of a role for oxidant stress in shifting arachidonic acid metabolism
toward an increased production of thromboxane has been identified previously (2, 3, 34),
and the results of the present study suggest that a comparable effect may be occurring in
the vasculature of OZR, with the net result of a blunted vascular response to stimuli that
are dependent on PGI2 production for their full manifestation.
To better evaluate this statement, isolated skeletal muscle resistance arterioles from
LZR and OZR were exposed to acute reductions in oxygen tension under control
conditions and in response to either PGH2/TxA2 receptor blockade with SQ-29548 or
thromboxane synthase inhibition with CHI (Figure 4). Although these pharmacological
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challenges had no consistent impact on hypoxic dilation in arterioles from LZR, both
interventions resulted in improved dilator reactivity in response to reduced PO2 in arterioles
of OZR. Taken with the previous results, these data clearly suggest that an increased
production of TxA2 contributes to the impaired hypoxic dilation in arterioles of OZR.
However, the data presented in Figure 4 do not allow for discrimination between increased
vascular production of TxA2, an increased vascular sensitivity to produced TxA2, or an
altered vascular sensitivity to produced PGI2.
In order to assess this final issue, isolated arterioles from both rat strains were
challenged with increasing concentrations of thromboxane or prostacyclin (Figure 5).
Vasoconstrictor reactivity to thromboxane was very similar between arterioles of LZR and
OZR, and in both cases constrictor responses to thromboxane were largely independent of
oxidant stress (i.e., no identifiable impact of treatment with PEG-SOD) and were abolished
by blockade of the PGH2/TxA2 receptor. These observations suggest that the vascular
sensitivity to thromboxane is not significantly impacted by the presence of the metabolic
syndrome.

In contrast, vascular reactivity to prostacyclin was significantly reduced in

arterioles of OZR and this impairment was blunted following a reduction in oxidant stress
with PEG-SOD.

Whether this impaired response to PGI2 represents oxidant radical

degradation of prostacyclin (leading to the production of isoprostanes), altered function at
the level of the prostacyclin receptor, the impact of elevated oxidant stress on the
intracellular signaling cascade distal to the receptor, or a combination of these effects
remains to be determined.
In summary, with the evolution of the metabolic syndrome in obese Zucker rats, the
dilator responses of skeletal muscle resistance arterioles following acute reductions in
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oxygen tension are significantly attenuated.

Both biochemical and pharmacological

evidence suggests that this impaired dilator reactivity may be the result of an increase in
vascular production of thromboxane with reduced PO2 which could represent a constrictor
influence which competes against the dilator effects of prostacyclin (the production of
which appears to be largely intact).

Normalizing vascular oxidant stress blunts the

increased reduced PO2-induced production of thromboxane in vessels from OZR and also
increases the responsiveness of arterioles of OZR to exogenously supplied prostacyclin,
thus leading to an improvement in the mechanical response of the vessel to reduced
oxygen tension. The present study provides no compelling evidence that skeletal muscle
arteriolar sensitivity to thromboxane is altered with the progression of the metabolic
syndrome.
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Table 1. Baseline characteristics of LZR and OZR and for isolated arterioles in the present study. *

p<0.05 vs. LZR.

LZR

OZR

Mass (g)

361±7

664±9*

MAP (mmHg)

108±4

124±4*

[Glucose]blood (mg/dl)

102±5

184±11*

[Insulin]plasma (ng/ml)

1.3±0.3

7.5±0.5*

89±9

137±11*

154±10

367±22*

Nitrotyrosineplasma (ng/ml)

15±4

58±7*

Inner Diameter – Active (μm)

104±4

102±5

Inner Diameter – Passive (μm)

172±5

156±4*

Active Tone (%)

39±2

35±3

[Total Cholesterol]plasma (mg/dl)
[Triglycerides]plasma (mg/dl)
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FIGURE LEGENDS
Figure 1. Dilator reactivity of isolated skeletal muscle resistance arterioles of LZR and
OZR in response to acute reductions in oxygen tension. Data, presented as mean±SEM,
are shown for arterioles under control conditions and following removal of the vascular
endothelium using air bolus perfusion (Panel A), inhibition of nitric oxide synthase with LNAME and/or inhibition of cyclooxygenase with indomethacin (Panel B), treatment with LNAME and/or indomethacin following incubation of the arteriole with the anti-oxidant PEGSOD (Panel C). Please see manuscript text for complete details. * p<0.05 vs. Control
responses in that strain; † p<0.05 vs. responses in LZR Control; ‡ p<0.05 vs. responses in
OZR + PEG-SOD.

Figure 2. Vascular production of 6-keto-PGF1α (Panel A; as an estimate of PGI2) and 11dehydro-TxB2 (Panel B; as an estimate of TxA2) by pooled arteries of LZR and OZR in
response to an acute reduction in oxygen tension. Data, presented as mean±SEM, are
shown for arteries under control conditions, and following pharmacological inhibition of
cyclooxygenases with indomethacin, and for 11-dehydro-TxB2, thromboxane synthase with
CHI. * p<0.05 vs. Control (21% O2) in that strain, † p<0.05 vs. 0% O2 in that strain; ‡
p<0.05 vs. responses in LZR 0% O2.

Figure 3. Vascular production of 6-keto-PGF1α (Panel A; as an estimate of PGI2) and 11dehydro-TxB2 (Panel B; as an estimate of TxA2) by pooled arteries OZR in response to an
acute reduction in oxygen tension. Data, presented as mean±SEM, are shown for arteries
under control conditions, following treatment of arteries with the anti-oxidant PEG-SOD,
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and following pharmacological inhibition of cyclooxygenases with indomethacin. * p<0.05
vs. responses under Control (21% O2) conditions, † p<0.05 vs. responses under 0% O2; ‡
p<0.05 vs. responses determined under 0% O2 conditions + PEG-SOD.

Figure 4. Dilator reactivity of isolated skeletal muscle resistance arterioles of LZR and
OZR in response to acute reductions in oxygen tension. Data (mean±SEM) are presented
for each strain under control conditions, and following pharmacological inhibition of the
PGH2/TxA2 receptor with SQ-29548 or thromboxane synthase with CHI. * p<0.05 vs. LZR
Control; † p<0.05 vs. OZR Control.

Figure 5. Vascular reactivity of isolated skeletal muscle resistance arterioles of LZR and
OZR (mean±SEM) in response to increasing concentrations of thromboxane under control
conditions and following treatment of vessels with PEG-SOD (Panel A) or SQ-29548
(Panel B), and increasing concentrations of prostacyclin under control conditions and
following treatment with PEG-SOD (Panel C). The term “max” represents the maximum
bound (the maximum change) in vessel diameter in response to increasing concentration
of either thromboxane or prostacyclin; estimated from the logistic regression equation
described in the “Materials and Methods”. * p<0.05 vs. Control responses within that
strain; † p<0.05 vs. responses in LZR under Control conditions.
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Figure 2.
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Figure 3.
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ABSTRACT
Objective: To determine if arachidonic acid (AA)-induced skeletal muscle arteriolar
dilation is altered with hypercholesterolemia in ApoE and LDLR gene deletion mice fed
normal diet.

This study also determined contributors to altered AA-induced dilation

between dyslipidemic mice and controls; C57/Bl/6J (C57).
Methods: Gracilis muscle arterioles were isolated, with mechanical responses assessed
following challenge with AA under control conditions and after elements of AA
metabolism pathways were inhibited. Conduit arteries from each strain were used to
assess AA-induced production of PGI2 and TxA2.
Results: Arterioles from ApoE and LDLR exhibited a blunted dilation to AA versus C57.
While responses were cyclooxygenase-dependent in all strains, inhibition of
thromboxane synthase or blockade of PGH2/TxA2 receptors improved dilation in ApoE
and LDLR only.

AA-induced generation of PGI2 was comparable across strains,

although TxA2 generation was increased in ApoE and LDLR. Arteriolar reactivity to
PGI2 and TxA2 was comparable across strains. Treatment with TEMPOL improved
dilation and reduced TxA2 production with AA in ApoE and LDLR.
Conclusions: These results suggest that AA-induced arteriolar dilation is constrained in
ApoE and LDLR via an increased production of TxA2. While partially due to elevated
oxidant stress, additional mechanisms contribute which are independent of acute
alterations in oxidant tone.
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INTRODUCTION
Dyslipidemia,

and

specifically

hypercholesterolemia,

has

repeatedly

been

demonstrated to represent a strong predisposing risk factor for the development of
coronary and peripheral arterial disease (1). While this increased risk for the progression
of vascular disease with hypercholesterolemia is most commonly associated with an
increased predisposition for the development of atherothromboses, atherosclerotic lesions
and plaque depositions (3, 10, 26), investigations into the impact of hypercholesterolemia
on vascular reactivity and endothelial function, potentially as contributing mechanisms to
vascular disease, is less clearly understood.
While some disparity in the prevailing literature exists (25), the general consensus is
that the development of hypercholesterolemia is usually associated with a significant
reduction in the bioavailability of endothelium-derived nitric oxide (5, 6, 23), with the
relatively predictable ensuing outcome of an impaired vascular reactivity in response to
stimuli that are considered to have a significant contribution from this signaling
molecule/pathway (i.e., flow-mediated dilation; ref. 12). In our recent study, we provided
evidence suggesting that development of familial hypercholesterolemia (a genetic disorder
resulting in exceptionally high low density lipoprotein [LDL] level, in the face of an otherwise
relatively normal lipid profile) in the LDL receptor gene deletion mouse or type III
hyperlipidemia (a condition wherein both LDL and plasma triglycerides are significantly
elevated) in the apolipoprotein E gene deletion mouse, was associated with a near
complete abolition of the bioavailability of endothelium-derived nitric oxide in response to
imposed stimuli (22). However, this loss of vascular nitric oxide bioavailability did not result
in a profound reduction in dilator reactivity, as an increased generation of dilator signaling
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molecules through 12/15 lipoxygenases emerged with evolution of the dyslipidemia (22),
suggesting that alterations to the metabolism of arachidonic acid may be associated with
hypercholesterolemia, and that these can have profound consequences for vascular
function.
In 1996, the work of Pfister and colleagues (16, 17) strongly suggested that dietinduced hypercholesterolemia in rabbits can lead to changes in arachidonic acid
metabolism, mediated via lipoxyegnase are cytochrome P450 epoxygenase enzymes,
causing profound alterations to dilator reactivity determined in isolated aortic segments.
Additionally, Srisawat et al. (21), while providing additional evidence that diet-induced
hypercholesterolemia results in impaired endothelium-dependent dilation in aortic rings,
determined that chronic treatment with indomethacin improved endothelial function, and
was associated with reductions in urinary levels of 2,3-dinor-thromboxane B2 and 8-isoPGF2α, a stable urinary breakdown product of thromboxane A2 and a marker of chronic
oxidant stress, respectively.

Most recently, Pfister demonstrated that impairments to

endothelium-dependent dilation in aortic rings of hypercholesterolemic rabbits were
diminished in a subgroup of animals lacking a functional thromboxane receptor (15).
These previous results suggest that a contributing mechanism underlying alterations to
vascular reactivity under conditions of hypercholesterolemia may involve both elevated
vascular oxidant stress and metabolism of arachidonic acid through cyclooxygenase
pathways. However, given recent observations in our laboratory (22) and by others (25)
suggesting that alterations to endothelium-dependent reactivity may reflect the specific
challenge imposed rather than a global impairment, we examined alterations to dilator
reactivity in response to direct challenge with arachidonic acid itself, wherein the
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bioavailability of endothelium-derived nitric oxide is not a significant contributing element to
the net mechanical response. Using both apolipoprotein E and LDL receptor gene deletion
mouse models of hypercholesterolemia, the hypothesis tested in the present study was
that arachidonic acid-induced dilator reactivity of skeletal muscle arterioles would be
impaired in the presence of profound dyslipidemia and that this would be the result of
alterations to either the production or vascular reactivity to metabolites of arachidonic acid
via cyclooxygenase, owing to the presence of an elevated oxidant stress.

MATERIALS AND METHODS
Animals: The present study used three strains of mice, the C57/Bl/6J (C57) as the control
strain and the apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low
density lipoprotein receptor gene deletion (B6.129S7-Ldlrtm1Her/J; LDLR) mice on the
C57/Bl/6J background.

All mice were purchased from Jackson Laboratories (Bar

Harbor, ME) at 6 weeks of age. The ApoE mouse manifests type III hyperlipidemia, in
which both plasma cholesterol and triglyceride levels are elevated, although the
elevations in LDL are not as severe as in the LDLR gene deletion mouse (19). In
contrast, the LDLR mouse is a model of human familial hypercholesterolemia,
manifesting a profound increase in serum LDL levels while ingesting a normal diet (11).
Male mice of each strain were fed standard chow and drinking water ad libitum and
were housed in an AAALAC-accredited animal care facility at the West Virginia University
Health Sciences Center and all protocols received prior IACUC approval. At 20 weeks of
age, after an overnight fast, mice were anesthetized with injections of sodium pentobarbital
(50 mg•kg-1 i.p.), and received tracheal intubation to facilitate maintenance of a patent
airway. In all mice, a carotid artery was cannulated for determination of arterial pressure.
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Blood aliquots were drawn from the jugular vein cannula for determination of glucose and
insulin (Linco), a lipid profile (Waco), and nitrotyrosine (Oxis).
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized
mice, the intramuscular continuation of the right gracilis artery was removed and
cannulated, as described previously (8). These first order arterioles were extended to
their approximate in situ length and were equilibrated at 80% of the animal's mean
arterial pressure in order to approximate the in vivo intralumenal pressure experienced
by the animal (13).

Following equilibration, arteriolar reactivity was evaluated in

response to increasing concentrations of arachidonic acid (10-10 M – 10-6 M; Sigma).
Additionally, in select experiments arteriolar reactivity was also evaluated in response to
increasing concentrations of prostacyclin (PGI2; 10-10 M – 10-6 M; Biomol) or carbocyclic
thromboxane A2 (TxA2; 10-10 M – 10-6 M; Cayman).
Removal of the arteriolar endothelium was accomplished by passing an air bolus
through the perfusate line into the isolated microvessel, the efficacy of which was
determined from a loss of all dilator reactivity in response to application of 10-6 M
acetylcholine (8). To assess the contribution of nitric oxide production or the generation
of metabolites via cyclooxygenase as mediators of arteriolar reactivity, isolated vessels
were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (LNAME; 10-4 M for 45 minutes prior to agonist challenge; Sigma) or the cyclooxygenase
antagonist indomethacin (INDO; 10-6 M for 60 minutes prior to agonist challenge;
Sigma), respectively. To determine the contribution of metabolites of arachidonic acid
mediated via cytochrome P450 enzymes, vessels were treated with the suicide
substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M for 60 minutes prior to
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agonist challenge; Sigma).

Previous studies have demonstrated that 17-ODYA

profoundly attenuates both the ω-hydroxylation (producing 20-hydroxyeicosatetraenoic
acid; 20-HETE) and epoxygenation (producing epoxyeicosatrienoic acids; EETs)
reactions of arachidonic acid through cytochrome P450 (24), thus preventing changes
to vascular levels of 20-HETE or EETs as contributing mediators to endotheliumdependent dilation.

To assess the contribution of lipoxygenase metabolites to the

patterns of arteriolar dilation, vessels were treated with nordihydroguaiaretic acid
(NDGA; 3×10-5 M for 45 minutes prior to agonist challenge; Biomol), a selective inhibitor
of 12/15-lipoxygenases (20, 27). To antagonize vascular PGH2/TxA2 receptors, vessels
were treated with SQ-29548 (10-5 M for 30 minutes prior to agonist challenge; Biomol),
while inhibition of thromboxane synthase was accomplished using carboxyheptyl
imidazole (CHI; 10-5 M for 45 minutes prior to agonist challenge; Biomol).
vascular

oxidant

tone,

arterioles

were

treated

with

To reduce

4-Hydroxy-2,2,6,6-

tetramethylpiperidine-1-15N-oxyl (TEMPOL; 10-4M for 60 minutes prior to agonist
challenge, Sigma).
Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6keto-prostaglandin F1α (6-keto-PGF1α; the stable breakdown product of PGI2; ref. 14), and
11-dehydro-thromboxane B2 (11-dehydro-TxB2; the stable plasma breakdown product of
TxA2; ref. 4) in response to challenge with arachidonic acid within the three mouse strains
was assessed using pooled conduit arteries (femoral, saphenous, iliac, carotid arteries)
from each mouse. Vessels were incubated in microcentrifuge tubes in 1 ml of physiological
salt solution for 30 minutes under control conditions (21% O2), after which time arachidonic
acid (10-6 M) was added to the tube for an additional 30 minutes. After the second 30
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minute period, the PSS was transferred to a new tube, frozen in liquid N2 and stored at 80°C. Metabolite release by the vessels was determined using commercially available EIA
kits for 6-keto-PGF1α and 11-dehydro-TxB2 (Cayman).
Data and Statistical Analyses: Active tone of individual arterioles at the equilibration
pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest
in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the
equilibration pressure in Ca2+-free PSS.
Dilator responses of isolated arterioles following challenge with dilator agonists were
fit with the three-parameter logistic equation:

⎡ max − min ⎤
y = min+ ⎢
log ED50 −x ⎥
⎣1 + 10
⎦
where y represents the change in arteriolar diameter, “min” and “max” represent the lower
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist
concentration, x is the logarithm of the agonist concentration and log ED50 represents the
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between
the lower and upper bounds.
Data are presented as mean±SEM. Statistically significant differences in measured
and calculated parameters in the present study were determined using analysis of variance
(ANOVA). In all cases, Student-Newman-Keuls post hoc test was used when appropriate
and p<0.05 was taken to reflect statistical significance.

RESULTS
Table 1 presents baseline characteristics of the mouse groups in the present study.
While all mice were of similar mass at 20 weeks of age, LDLR experienced a significant
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elevation in mean arterial pressure and fasting insulin concentration versus values in C57
or ApoE. Additionally, both ApoE and LDLR manifested a profound hypercholesterolemia,
most severe in LDLR. Further, ApoE exhibited a significant hypertriglyceridemia as well,
while plasma triglyceride levels in LDLR were not different from that in C57. Finally,
plasma levels of nitrotyrosine, a marker of chronic elevations in oxidant stress, were
significantly elevated in ApoE and LDLR as compared to C57. With regard to basal
vascular tone, isolated arterioles from all mouse groups demonstrated a comparable
resting active diameter and passive (calcium-free) diameter, such that no significant
difference in active tone was calculated between C57, ApoE and LDLR in the present
study.
Data summarizing the dilator responses of skeletal muscle resistance arterioles
from C57, ApoE and LDLR in response to challenge with increasing concentrations of
arachidonic acid are presented in Figure 1. Under control conditions, the reactivity of
arterioles from ApoE and LDLR, while not significantly different from each other, both
demonstrated a reduction in their maximum bound as compared to responses in arterioles
from C57. Endothelium-denudation via perfusion with an air bolus eliminated mechanical
responses of vessels across the three strains in response to application of arachidonic
acid.
The effects of pharmacological blockade of lipoxygenases and cyclooxygenases
with NDGA and INDO, respectively, on arachidonic acid-induced vasodilation in isolated
arterioles are summarized in Figure 2. In arterioles from C57 (Panel A), blockade of
lipoxygenases with NDGA had no impact on dilator responses to arachidonic acid, while
treatment with indomethacin abolished all dilation to arachidonic acid. Arterioles from
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ApoE, while demonstrating a blunted overall reactivity to arachidonic acid, also
experienced a severe reduction in dilator reactivity following cyclooxygenase inhibition with
indomethacin (Panel B).

However, while treatment with NDGA alone did not impact

arachidonic acid-induced dilation in vessels from ApoE, application of NDGA to vessels
that had been treated with indomethacin eliminated the residual dilation in response to
arachidonic acid that remained following cyclooxygenase inhibition alone.

Finally,

arterioles from LDLR appeared to demonstrate a dilator response to arachidonic acid
challenge that was dependent on the production of metabolites generated via both
lipoxygenases and cyclooxygenases, as antagonists to these pathways given in isolation
resulted in modest reductions to the compromised level of reactivity, while treatment with
both NDGA and indomethacin abolished all arachidonic acid-induced reactivity (Panel C).
Treatment of isolated arterioles from C57, ApoE or LDLR with either L-NAME or 17-ODYA
did not result in either significant or consistent effects of dilator responses following
challenge with increasing concentrations of arachidonic acid (data not shown).
Figure 3 presents the effects of antagonizing thromboxane A2 generation (with CHI)
and action (with SQ-29548) on dilator responses of skeletal muscle arterioles in the
present study. In control animals, application of either CHI or SQ-29548 had no impact on
arteriolar dilation in response to increasing concentrations of arachidonic acid (Panel A). In
contrast, arterioles from both ApoE (Panel B) and LDLR (Panel C) exhibited a significant
improvement to their degree of arachidonic acid-induced dilation relative to untreated
conditions following either inhibition of thromboxane synthase with CHI or blockade of the
PGH2/TxA2 receptor (SQ-29548).

63

Data describing the arachidonic acid-induced generation of the cyclooxygenase
products PGI2 (estimated from levels of 6-keto-PGF1α) and TxA2 (estimated from levels of
11-dehydro TxB2) from pooled arteries of the three mouse groups in the present study are
summarized in Figure 4. Following application of 10-6 M arachidonic acid, arteries from
C57, ApoE and LDLR all demonstrated a significant increase in PGI2 release, the degree of
which was comparable between the three mouse strains (Panel A).

In contrast,

arachidonic acid-induced generation of TxA2, while statistically significant in arteries from
C57, demonstrated a substantially more robust response in vessels from both ApoE and
LDLR (Panel B). Pre-treatment of pooled vessels with either CHI or indomethacin severely
attenuated all arachidonic acid-induced TxA2 generation in all three strains.
Arteriolar reactivity in response to challenge with prostacyclin (Panel A) or
carbocyclic thromboxane A2 (Panel B) in the three mouse groups is summarized in Figure
5. In response to increasing concentrations of prostacyclin, arterioles from C57 and ApoE
demonstrated a very similar degree of dilator reactivity, although this response
demonstrated a trend toward impairment in vessels from LDLR as compared to that in
vessels from either other strain (Panel A). Arterioles from all three mouse strains exhibited
very similar patterns of constrictor reactivity in response to challenge with increasing
concentrations of carbocyclic thromboxane A2 (Panel B).
Figure 6 presents the effects of treating vessels with the antioxidant TEMPOL, the
thromboxane synthase inhibitor CHI, or both, on arteriolar responses to increasing
concentrations of arachidonic acid. Addition of TEMPOL did not have a significant impact
on arteriolar diameter in vessels from any of the three mouse strains under resting
conditions. In arterioles from C57 (Panel A), neither treatment with TEMPOL nor CHI had
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a significant impact on dilator reactivity to arachidonic acid. In contrast, for arterioles from
both ApoE (Panel B) and LDLR (Panel C), treatment with either TEMPOL or CHI
significantly improved dilator responses to arachidonic acid, with the effects of CHI being
stronger than that for TEMPOL.

Interestingly, in both ApoE and LDLR, combined

treatment with CHI and TEMPOL did not have any effect on arachidonic acid-induced
dilation beyond that determined for CHI treatment alone.
Figure 7 presents data describing the effects of treating arteries from C57, ApoE or
LDLR with TEMPOL on arachidonic acid-induced thromboxane A2 production.

While

treatment with the antioxidant had an insignificant impact on vascular thromboxane
production in C57, incubation of vessels with TEMPOL significantly reduced the
arachidonic acid-induced production of TxA2 in both ApoE and LDLR.

However, this

reduction in thromboxane generation was only partial in nature, and levels of TxA2
production in response to challenge with arachidonic acid following treatment with
TEMPOL remained significantly increased versus that in untreated arteries from ApoE and
LDLR.

DISCUSSION
Although hypercholesterolemia represents a powerful risk factor for the
development of peripheral artery disease (1), the effects of hypercholesterolemia on
vascular reactivity and endothelial function is less clearly understood. Given recent studies
suggesting that diet-induced hypercholesterolemia can alter arachidonic acid metabolism
and profoundly impact vascular reactivity through signaling mechanisms associated with
the generation of thromboxane A2 (15, 18, 21), the present study determined the effects of
genetic hypercholesterolemia on the dilator reactivity of skeletal muscle resistance
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arterioles in response to challenge with arachidonic acid. More specifically, the hypothesis
tested in this study was that arachidonic acid-induced arteriolar dilation in ApoE and LDLR
would be impaired owing to either the production of, or vascular reactivity to, metabolites of
arachidonic acid via cyclooxygenase, and that these alterations would be associated with
an elevated oxidant stress.
Contrary to our results with dilator stimuli that are more strongly dependent on the
bioavailability of endothelium-derived nitric oxide, where reactivity was largely maintained in
the face of a profound reduction in this parameter (22), the results presented in Figure 1
indicate that skeletal muscle arteriolar dilation in response to increasing concentrations of
arachidonic acid was significantly reduced in both ApoE and LDLR as compared to
responses determined in C57. Interestingly, the data presented in this figure also strongly
suggest that not only is the overwhelming majority of dilator reactivity in response to
arachidonic acid dependent on a functional endothelium in control animals, the
impairments to arteriolar dilation with this stimulus may also originate with alterations to
endothelial function, rather than within vascular smooth muscle.
While results from the present study did not demonstrate a role for either nitric oxide
bioavailability or for metabolites of arachidonic acid mediated via cytochrome P450
enzymes in terms of contributing to the arachidonic acid-induced dilator reactivity of
skeletal muscle arterioles in any of the three mouse strains, activity mediated through
cyclooxygenase (and to a lesser extent lipoxygenase) were critical. While arteriolar dilation
in response to arachidonic acid was mediated entirely via cyclooxygenase in vessels from
C57, vessels from ApoE and LDLR demonstrated a dilator response that was increasingly
a function of metabolites via both cyclooxygenase and lipoxygenase, with this effect being
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more pronounced in LDLR than in ApoE, where the response was still predominantly
cyclooxygenase-dependent.

However, the data presented in Figure 2 do not provide

significant insight into the impaired dilator reactivity demonstrated in arterioles of ApoE and
LDLR in response to challenge with arachidonic acid beyond the critical involvement of
cyclooxygenase.

Given previous studies suggesting that the development of the

hypercholesterolemic condition can profoundly impact arachidonic acid metabolism in
general (7, 18), and the recent studies from both Pfister (15) and Srisawat et al. (21) that
implicate altered behavior mediated through thromboxane generation/action as contributing
mechanism to altered patterns of vascular reactivity with hypercholesterolemia, we treated
vessels from ApoE and LDLR with an inhibitor of thromboxane synthase (CHI) or an
antagonist for the PGH2/TxA2 receptor (SQ-29548). As shown in Figure 3, while neither of
these agents had a significant role in the dilator responses in arterioles from C57,
application of either CHI or SQ-29548 resulted in a significant improvement in the dilator
responses of arterioles from ApoE or LDLR in response to challenge with increasing
concentrations of arachidonic acid. Interestingly, the ameliorative effect was comparable
with either pharmacological agent. While this implicates either increased thromboxane
generation or an increased gain/sensitivity at the vascular thromboxane receptor as
contributing mechanisms to the impaired arachidonic acid-induced arteriolar dilation, these
data do not provide insight into which component may be most responsible. However,
these data do strongly suggest that the development of a thromboxane-sensitive
component which may act to constrain arachidonic acid-induced arteriolar dilation
accompanies the evolution of genetic hypercholesterolemia.
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As both CHI and SQ-29548 elicited similar improvements to arteriolar dilation in
response to arachidonic acid challenge in ApoE and LDLR, it was necessary to discern
which processes contributed to the constrained dilator reactivity: 1) increasing
thromboxane A2 production in response to arachidonic acid production, 2) increased
vascular reactivity to produced thromboxane A2, or both. The data presented in Figure 4
indicate that arachidonic acid-induced generation of PGI2 (estimated from 6-keto-PGF1α
levels) remained intact in arteries of ApoE and LDLR as compared to that determined in
C57, an observation that is consistent with previous studies in the coronary vasculature of
ApoE mice (9).

In contrast, arachidonic-acid induced generation of thromboxane A2

(estimated from 11-dehydro-TxB2 levels) was significantly increased with the evolution of
genetic hypercholesterolemia in ApoE and LDLR. When taken together with data in Figure
5, which suggest that the sensitivity of resistance arterioles from ApoE and LDLR in
response to increasing concentrations of either prostacyclin or thromboxane A2 is not
dramatically altered from that determined for C57 control mice, these data may provide
compelling evidence that a predominant contributing mechanism underlying the
constrained arteriolar dilation with increasing concentrations of arachidonic acid may be the
development of an increased generation of the constrictor prostanoid thromboxane A2,
which antagonizes the dilator effects associated with the generation of prostacyclin.
Given that previous studies have clearly demonstrated the critical role for elevated
oxidant tone in the increased generation of thromboxane through cyclooxygenase in
response to challenge with arachidonic acid (2, 28, 29), and our observations of an
increase in the plasma levels of nitrotyrosine in the ApoE and LDLR as compared to that
determined in C57, the data presented in Figures 6 and 7 provide some insight into the
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potential role that elevated vascular oxidant tone may play in the increased arachidonic
acid-induced thromboxane A2 generation with genetic dyslipidemia. While treatment with
TEMPOL had no impact on arachidonic acid-induced dilation or TxA2 generation in
arterioles from C57, it significantly improved the dilator response in microvessels from both
ApoE and LDLR and reduced the levels of TxA2 production. However, in vessels from both
strains, this improvement in dilator reactivity following treatment with the antioxidant was
less pronounced than that determined following treatment with the inhibitor of thromboxane
synthase, CHI. Further, combined treatment with both TEMPOL and CHI did not result in
an improvement beyond that determined with CHI treatment alone. Additionally, while pretreatment of pooled vessels with TEMPOL lowered arterial thromboxane production in
response to challenge with arachidonic acid, the levels of thromboxane production
remained significantly elevated despite the addition of the antioxidant. Taken together
these results suggest that, while an enhanced arachidonic acid-induced genesis of
thromboxane A2 via thromboxane synthase represents a strong contributor to the
constrained dilator reactivity in skeletal muscle arterioles of ApoE and LDLR mice, the
presence of an elevated vascular oxidant tone may represent a partial contributor to this
shift in the metabolism of arachidonic acid.

Clearly, these results suggest that other

parameters, independent of acute changes in vascular oxidant tone, also contribute to this
increased generation of thromboxane A2. Potential avenues for ongoing investigation in
this regard can include the study of not only the effects of chronic elevations in vascular
oxidant tone, but also the progression of a chronic state of inflammation associated with
dyslipidemia (10, 26) and how these processes can ultimately impact pathways of
arachidonic acid metabolism.
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In summary, with the development of genetic hypercholesterolemia in ApoE and
LDLR mice, the dilator reactivity of skeletal muscle resistance arterioles in response to
increasing concentrations of arachidonic acid is impaired.

This impairment does not

appear to be associated with a reduction in the generation/release of, or an altered
arteriolar reactivity to, prostacyclin.

However, with the evolution of this dyslipidemic

condition, there appears to be an increase in the arachidonic acid-induced generation of
the vasoconstrictor metabolite thromboxane A2. While there does not appear to be an
alteration to the arteriolar constrictor reactivity to thromboxane, the increased generation of
this metabolite may compete with the dilator effects of prostacyclin, thus limiting net dilator
reactivity in response to arachidonic acid. Further, while an increase in vascular oxidant
stress appears to contribute to this response, additional mechanisms which are
independent of acute alterations to oxidant tone also contribute to this effect.

Future

investigation will be required to discern which mechanistic alterations associated with the
development of hypercholesterolemia contribute to the increased production of
thromboxane A2, and what the implications of this shift in the metabolism of arachidonic
acid are for issues such as the integrated control of tissue perfusion, tissue oxygenation
and the protection from atherogenesis and atherothrombosis.
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Table 1. Baseline characteristics of mice and individual arterioles used in the present
study. * p<0.05 vs. C57; † p<0.05 vs. ApoE.

C57

ApoE

LDLR

Mass (g)

33±2

34±2

33±2

MAP (mmHg)

88±4

92±3

106±5*†

[Glucose]blood (mg/dl)

84±7

103±11

115±7*

[Insulin]plasma (ng/ml)

1.1±0.3

1.6±0.3

2.8±0.5*

[Total Cholesterol]plasma (mg/dl)

88±9

288±17*

364±22*†

[LDL Cholesterol]plasma (mg/dl)

49±5

260±11*

338±19*†

[Triglycerides]plasma (mg/dl)

88±10

175±14*

116±18†

Nitrotyrosineplasma (ng/ml)

14±5

54±11*

60±14*

Inner Diameter – Active (μm)

54±4

55±5

51±4

Inner Diameter – Passive (μm)

128±5

122±4

118±7

Active Tone (%)

57±3

55±4

56±4
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FIGURE LEGENDS
Figure 1.

Data describing the dilator reactivity of isolated skeletal muscle resistance

arterioles of C57, ApoE and LDLR mice in response to increasing concentrations of
arachidonic acid.

Data, presented as mean±SEM, are shown for arterioles under control

conditions and following removal of the vascular endothelium using air bolus perfusion
(please see text for details). n=6 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs.
control within that strain.

Figure 2. Data describing the dilator responses of isolated skeletal muscle resistance
arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to
increasing concentrations of arachidonic acid. Data, presented as mean±SEM, are shown
for arterioles under control conditions, and following pharmacological inhibition of
cyclooxygenases with indomethacin, lipoxygenases with NDGA or combined inhibition of
both enzymatic pathways (please see text for details). n=5-10 animals for each group; *
p<0.05 vs. control conditions, † p<0.05 vs. no response.

Figure 3. Data describing the dilator responses of isolated skeletal muscle resistance
arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to
increasing concentrations of arachidonic acid. Data, presented as mean±SEM, are shown
for arterioles under control conditions, and following pharmacological inhibition of
PGH2/TxA2 receptors with SQ-29548 and thromboxane synthase with CHI (please see text
for details). n=6-7 animals for each group; * p<0.05 vs. control conditions.
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Figure 4. Data describing the arterial production of prostacyclin (as 6-keto-PGF1α; Panel
A) or thromboxane A2 (as 11-dehydro TxB2; Panel B) from C57, ApoE and LDLR in
response to 10-6 M arachidonic acid. Data, presented as mean±SEM, are shown under
control conditions, and following pharmacological inhibition of cyclooxygenase with
indomethacin or thromboxane synthase (with CHI), as appropriate. n=8 animals for each
group, with each n representing pooled arteries from an individual mouse; please see text
for details. * p<0.05 vs. respective control; † p<0.05 vs. C57 under that condition; ‡ vs.
ApoE under that condition.

Figure 5.

Data (mean±SEM) describing the reactivity of isolated skeletal muscle

resistance arterioles of C57, ApoE and LDLR mice in response to increasing
concentrations of prostacyclin (Panel A) or carbocyclic thromboxane A2 (Panel B). n=6
animals for each group, no significant differences were identified in the vascular reactivity
in response to increasing concentrations of prostacyclin or thromboxane A2.

Figure 6. Data, presented as mean±SEM, describing the dilator responses of isolated
skeletal muscle resistance arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel
C) mice in response to increasing concentrations of arachidonic acid. Data are shown for
arterioles under control conditions, following treatment of vessels with the antioxidant
TEMPOL, following pharmacological inhibition of thromboxane synthase with CHI, and
following treatment with both TEMPOL and CHI. n=8-10 animals for each group; * p<0.05
vs. control conditions; † p<0.05 vs. treatment with TEMPOL alone.
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Figure 7. Data describing the arterial production of thromboxane A2 (as 11-dehydro TxB2;
Panel B) from C57, ApoE and LDLR in response to 10-6 M arachidonic acid.

Data,

presented as mean±SEM, are shown under control conditions, and following treatment of
pooled arteries with the antioxidant TEMPOL (10-4 M). n=6 animals for each group, with
each n representing pooled arteries from an individual mouse; please see text for details. *
p<0.05 vs. within-strain/no arachidonic acid; † p<0.05 vs. within-strain/with arachidonic
acid.
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ABSTRACT
Object: The obese Zucker rat (OZR) model of the metabolic syndrome is partly
characterized by moderate hypercholesterolemia in addition to other contributing comorbidities. Previous results suggest that vascular dysfunction in OZR is associated
with chronic reduction in vascular nitric oxide (NO) bioavailability and chronic
inflammation, both frequently associated with hypercholesterolemia.

As such, we

evaluated the impact of chronic cholesterol reducing therapy on the development of
impaired skeletal muscle arteriolar reactivity and microvessel density in OZR and its
impact on chronic inflammation and NO bioavailability.

Materials and Methods:

Beginning at 7 weeks of age, male OZR were treated with gemfibrozil, probucol,
atorvastatin or simvastatin (in chow) for 10 weeks. Subsequently, plasma and vascular
samples were collected for biochemical/molecular analyses, while arteriolar reactivity
and microvessel network structure were assessed using established methodologies
after 3, 6 and 10 weeks of drug therapy.

Results: All interventions were equally

effective at reducing total cholesterol, although only the statins also blunted the
progressive

reductions

to

vascular

NO

bioavailability,

evidenced

by

greater

maintenance of acetylcholine-induced dilator responses, an attenuation of adrenergic
constrictor reactivity, and an improvement in agonist-induced NO production.
Comparably, while minimal improvements to arteriolar wall mechanics were identified
with any of the interventions, chronic statin treatment reduced the rate of microvessel
rarefaction in OZR. Associated with these improvements was a striking statin-induced
reduction in inflammation in OZR, such that numerous markers of inflammation were
correlated with improved microvascular reactivity and density.
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However, using

multivariate discriminant analyses, plasma RANTES, IL-10, MCP-1 and TNF-α were
determined to be the strongest contributors to differences between groups, although
their relative importance varied with time. Conclusions: While the positive impact of
chronic statin treatment on vascular outcomes in the metabolic syndrome are
independent of changes to total cholesterol, and are more strongly associated with
improvements to vascular NO bioavailability and attenuated inflammation, these results
provide both a spatial and temporal framework for targeted investigation into
mechanistic determinants of vasculopathy in the metabolic syndrome.
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INTRODUCTION
Arising from a chronic hyperphagia which originates due to non-functional leptin
receptor gene and an impaired satiety reflex (5, 23), the obese Zucker rat (OZR) rapidly
develops insulin resistance, hypertriglyceridemia and a moderate hypertension (43).
Combined with the parallel creation of a pro-thrombotic, pro-oxidant and pro-inflammatory
environment, OZR are considered to be an excellent model for the clinical condition termed
the metabolic syndrome (47). Associated with these systemic pathologies, we and others
have defined numerous impairments to microvascular structure and function in OZR which
negatively impact skeletal muscle perfusion, both under resting conditions (15, 18, 19), in
response to elevated metabolic demand (18, 19, 50, 51), following recovery from vascular
occlusion (15) and during hemorrhage (16). Chronic treatment of the metabolic syndrome
with exercise (13, 52) or of individual contributing elements through pharmacological
intervention (10, 16, 17, 48) have resulted in improvements to microvascular outcomes, as
well as to perfusion responses within skeletal muscle (13, 52), and have implicated
potential mechanisms through which these improvements may be manifested. Recently,
results from our laboratory have suggested that the chronic reduction in vascular nitric
oxide (NO) bioavailability that accompanies development of the metabolic syndrome in
OZR is well correlated with the severity of the reduction in skeletal muscle microvessel
density (16).

Ongoing studies have also suggested that while this microvascular

rarefaction is hypertension-independent (17), exercise-based interventions that not only
increase vascular NO bioavailability, but also blunt the severity of the chronic inflammatory
state in OZR, may be an excellent predictor of the ability to prevent microvessel loss within
the periphery (13).
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Within the metabolic syndrome in OZR is an elevation in plasma cholesterol levels
that, while consistent, is more moderate as compared to the profound elevations
determined for plasma triglycerides.

Given the severity of many indices of vascular

dysfunction in OZR, the extent to which elevated plasma cholesterol contributes to these
impairments in currently unclear.

However, treatment of hypercholesterolemia with 3-

hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitors (“statins”) has not
only the well-documented impact of lowering circulating plasma LDL and total cholesterol
levels (21, 35), but also has been identified as having the beneficial impacts of increasing
vascular NO bioavailability (3, 34) and blunting plasma markers of chronic inflammation
(11, 32, 35). Notably, it has been suggested that improvements to vascular function in
human subjects or animals afflicted with hypercholesterolemia may reflect these pleiotropic
effects of statin therapy rather than the direct impact of anti-cholesterol therapy itself (3, 26,
31). However, the extent to which these reflect independent ameliorative effects or effects
which are strongly correlated remains unclear.
The purpose of the present study was to determine the impact of chronic anticholesterol therapy on the temporal development of impairments to microvascular reactivity
and network structure in skeletal muscle of OZR manifesting the metabolic syndrome.
Further, the present study also attempted to demonstrate differences in treatment
effectiveness of more recently developed statin medications as compared to traditional
anti-cholesterol medications that do not fall into this category. The tested hypothesis was
that chronic ingestion of anti-cholesterol therapies would better maintain microvascular
structure and function in OZR, although the benefit of these effects would be due to
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improvements in vascular NO bioavailability and chronic inflammation, rather than effects
on plasma cholesterol per se.
MATERIALS AND METHODS
Animals: Male lean (LZR) and OZR (Harlan) fed standard chow and drinking water (see
below) ad libitum were housed at the West Virginia University Health Sciences Center and
all protocols received prior IACUC approval.

At 6-7 weeks of age, LZR and OZR were

divided into five groups within each strain:
1. control (maintained on normal chow)
2. treatment with gemfibrozil [GEM; maintained on chow containing 50 mg/kg/d
gemfibrozil, a fibric acid derivative and PPARα agonist (24)],
3. treatment with probucol [PRO; maintained on chow containing 100 mg/kg/d probucol,
an agent which increases fractional rate of LDL catabolism during cholesterol
elimination. While probucol has moderate anti-oxidant properties, these appear to be a
function of the LDL reducing effects of the drug rather than direct anti-oxidant effects
(24)].
4. treatment with simvastatin [SIM: maintained on chow containing 20 mg/kg/d
simvastatin, a cholesterol lowering agent via potent inhibition of HMG Co-A reductase
(24, 53), which also possesses anti-inflammatory properties associated with improved
NO bioavailability (12, 26, 28)].
5. treatment with atorvastatin [ATOR; maintained on chow containing 10 mg/kg/d
atorvastatin, a cholesterol lowering agent via potent inhibition of HMG Co-A reductase
(24, 53), which also possesses anti-inflammatory properties associated with improved
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NO bioavailability (4, 25)]. The primary difference between SIM and ATOR may be that
SIM has a greater capacity to elevate HDL-C than ATOR (9, 24, 28).
Rats were maintained on each of these groups for 3-4 weeks, 6-7 weeks or 10-11
weeks, at which time animals were used for experimentation (at 10, 13 and 17 weeks of
age, respectively). On the day of the experiment, following an 8 hour fasting period, rats
were anesthetized with injections of sodium pentobarbital (50 mg/kg, i.p.), and received
tracheal intubation to facilitate maintenance of a patent airway. In all rats, a conduit artery
was cannulated for determination of arterial pressure and for infusion of supplemental
anesthetic and drugs, as necessary. Blood samples were drawn from the cannula for
determination of glucose and insulin concentrations (Linco) as well as cholesterol and
triglyceride levels (Waco).

Plasma markers of inflammation were determined using

commercially available ELISA systems (Luminex; Linco).
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In all rats, the
intramuscular continuation of the right gracilis arteriole was removed and cannulated
(19). Within an individual group (above), vessels were divided into two sub-groups
following an equilibration period. Group 1 examined dilator responses, where arteriolar
reactivity was evaluated in response to application of acetylcholine (10-10 M – 10-5 M)
and sodium nitroprusside (10-6 M) to assess reactivity to NO from both endotheliumdependent and independent agonists, respectively. Subsequently, vessels were treated
with TEMPOL (10-4 M) to assess the contribution of vascular oxidant tone to agonistinduced dilation. Group 2 examined constrictor reactivity, and mechanical responses
were determined following challenge with phenylephrine (10-10 M – 10-7 M).
Subsequently, vessels were treated with TEMPOL or L-NAME (10-4 M) to assess the
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contribution of vascular oxidant tone and endothelium-dependent NO production to the
adrenergic constriction.
In all vessels, following the completion of the above procedures, the perfusate
and superfusate were replaced with Ca2+-free PSS and vessels were treated with 10-7 M
phenylephrine until all tone was abolished. At this time, intralumenal pressure within the
vessel was altered, in 20 mmHg increments, between 0 mmHg and 160 mmHg and the
inner and outer diameter of arterioles was determined at each pressure. These data
were used to calculate arteriolar wall mechanics which were used as indicators of
structural alterations to the microvessel wall (2, 20).
Measurement of Vascular NO Bioavailability: From a cohort of rats within the oldest
group (17 weeks of age), the abdominal aorta was removed and vascular NO
production was assessed using amperometric sensors (World Precision Instruments).
Briefly, aortae were isolated, sectioned longitudinally, pinned in a silastic coated dish
and superfused with warmed (37°C) PSS equilibrated with 95% O2 and 5% CO2. The
NO sensor (ISO-NOPF 100) was placed in close apposition to the endothelial surface
and a baseline level of current was obtained. Subsequently, increasing concentrations
of methacholine (10-10–10-6 M) were added to the bath and the changes in current were
determined. To verify that responses represented NO release, these procedures were
repeated following treatment of the aortic strip with L-NAME (10-4 M).
Histological Determination of Microvessel Density: At the conclusion of all muscle
perfusion protocols, the gastrocnemius muscle from the left leg was removed, rinsed in
PSS and fixed in 0.25% formalin. Muscles were embedded in paraffin and cut into 5 μm
cross sections. Sections were incubated with Griffonia simplicifolia I lectin (Sigma), for
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subsequent determination of microvessel density (20, 21).
Analyses of eNOS Expression and Activity: For determination of NOS expression,
skeletal muscle arteries were homogenized and proteins within the homogenate were
separated under denaturing conditions on an 8% SDS-polyacrilamide gel, after which
proteins were transferred to a PVDF membrane and blocked. Subsequently, blots were
incubated with mouse anti-eNOS/NOS Type III mAb (BD Transduction Laboratories),
washed and incubated with appropriate horseradish peroxidase conjugated secondary
antibody.

GE Healthsciences ECL advance kits were used to visualize proteins.

Additionally, in the oldest cohort of rats, the ascending and thoracic aorta, along with
non-cannulated carotid, femoral, saphenous and iliac arteries were removed and frozen
in liquid N2, for the subsequent determination of NOS activity using a commercially
available kit (Cayman).
Experimental Protocols:

Initially, the right gracilis muscle resistance arteriole was

removed for the evaluation of vascular reactivity and passive mechanical characteristics of
the vessel wall, described above.

Upon completion of these procedures, the right

gastrocnemius muscle was removed, cleared of non-muscular tissue, and its mass was
determined. This muscle was then used for determination of microvessel density, as
described above. Finally, the contralateral gastrocnemius muscle was removed for tissue
banking and the aortic and arterial segments were removed for assessment of NO
bioavailability and eNOS expression/activity, described above.
Data and Statistical Analyses: Mechanical responses of aortic rings following challenge
with acetylcholine or phenylephrine were fit with the three-parameter logistic equation:

⎡ max − min ⎤
y = min + ⎢
log ED50 −x ⎥
⎣1 + 10
⎦
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where y represents the change in isometric tension, “min” and “max” represent the lower
and upper bounds, respectively, of the change in arteriolar diameter with increasing agonist
concentration, x is the logarithm of the agonist concentration and log ED50 represents the
logarithm of the agonist concentration ( x ) at which the response ( y ) is halfway between
the lower and upper bounds.
Data are presented as mean±SEM. Statistically significant differences in measured
and calculated parameters in the present study were determined using analysis of variance
(ANOVA). In all cases, Student-Newman-Keuls post hoc test was used when appropriate
and p<0.05 was taken to reflect statistical significance. For analyses of inflammatory
markers between groups, we employed discriminant techniques to eliminate the univariate
nature of ANOVA and issues of independent variable co-linearity which minimizes the utility
of regression techniques. Discriminant analyses are based on canonical correlation to
maximize differences between a priori identified experimental groups. Multiple variables
are arranged into structural equations based upon their ceteris paribus ability to
distinguish those group differences. These stepwise analyses result in a rank ordering
of correlation coefficients in terms of their significance for the establishment of
differences between groups.

These produce a series of algebraic functions which

explain the differences between group centroids in the “x” dimension (Function 1), the
“y” dimension (Function 2).

Each function explains a specific percentage of the

variance between the group centroids.
RESULTS
Table 1 presents basic characteristics of animal groups within the present study.
OZR were consistently heavier than LZR, and this was not impacted by the anti-cholesterol

98

therapies.

While OZR ultimately developed a moderate hypertension as compared to

LZR, the development of the elevated blood pressure was attenuated in OZR-SIM and
OZR-ATOR groups. Fasting glucose was elevated in all OZR versus age matched LZR
after 10 weeks of age, although glycemic control was improved in OZR-SIM and OZRATOR groups, as the level of blood glucose was associated with reduced plasma insulin
with increasing age. The hypercholesterolemia in OZR was largely abolished as a result of
the four anti-cholesterol therapies, and there was a modest blunting of the
hypertriglyceridemia as a result of the PRO, SIM and ATOR treatments with age. Finally,
plasma levels of nitrotyrosine were elevated with age in OZR versus LZR, indicative of a
chronic elevation in oxidant stress, and this difference was blunted by chronic treatment
with probucol, simvastatin and atorvastatin.
The changes to skeletal muscle microvessel density with time in LZR and OZR, and
the impact of chronic treatment with the anti-cholesterol agents are summarized in Figure
1. Microvessel density was not significantly impacted by the evolution of the metabolic
syndrome at 7 weeks of age between LZR and OZR (Panel A), and as such, none of the
pharmacological treatments impacted this relationship. However, with increasing severity
of the metabolic syndrome over time, the degree of microvascular rarefaction was
increased between OZR and LZR (Panels B-D). Chronic treatment with GEM and PRO
had minor impacts on rarefaction in OZR, despite their effectiveness in reducing total
cholesterol.

In contrast, chronic treatment with either SIM or ATOR was effective at

delaying/blunting the progression of microvascular rarefaction in OZR at 10, 13 and 17
weeks of age.
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At both 7 (Panel A) and 10 weeks (Panel B) of age, regardless of experimental
group, both the arteriolar incremental distensibility and the circumferential stress versus
strain relationship (panel inset) was not different between LZR and OZR (Figure 2).
However, in both 13 week (Panel C) and 17 week (Panel D) old OZR, the slope coefficient
describing this parameter was significantly elevated in OZR as compared to LZR under
control conditions. While the anti-cholesterol therapies did not significantly impact this shift
in the stress versus strain relationship between arterioles of LZR and OZR at 13 weeks of
age, treatment with SIM or ATOR blunted this difference at 17 weeks of age, such that the
slope coefficients exhibited an intermediate phenotype between that for untreated LZR and
OZR.
Data describing arteriolar dilation in response to challenge with acetylcholine and
the impact of acute treatment of vessels with TEMPOL on the upper bound of this
relationship are summarized in Figure 3. At 7 weeks of age, the acetylcholine-induced
dilator reactivity of resistance arterioles from LZR and OZR was comparable, regardless of
experimental groups (Panel A) and the impact of anti-oxidant treatment on this response
was negligible (Panel B). A similar situation is present at 10 weeks of age, although
separation in the acetylcholine-induced dilation of resistance arterioles, while not
statistically significant between LZR and OZR, is becoming apparent (Panel C). However,
by 13 weeks of age (Panels E and F), and even more evident at 17 weeks of age (Panels
G and H), acetylcholine-induced dilation was significantly reduced in OZR versus LZR, and
this separation was blunted by treatment with SIM and ATOR. The impact of TEMPOL
treatment on this response also began to demonstrate differences, as treatment of
arterioles from OZR and OZR-GEM with the anti-oxidant resulted in a significant
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improvement in the upper bound of the acetylcholine-induced response. In all cases,
treatment of vessels with L-NAME abolished arteriolar responses to acetylcholine, and
arteriolar dilation in response to challenge with sodium nitroprusside was not different
between groups (data not shown).
Regardless of the pharmacological intervention imposed, arterial expression of
eNOS between LZR and OZR did not demonstrate a consistent or significant difference
between or within the two strains. Further, there was no evidence of a consistent or
significant impact of age on eNOS expression between LZR and OZR (data not shown).
Figure 4 summarizes arterial eNOS activity and methacholine-induced NO
production in the oldest cohort of LZR and OZR under the conditions of the present study.
At 17 weeks of age, eNOS activity (Panel A) was not significantly different between LZR
and OZR, and treatment with the anti-cholesterol therapies was without consistent effect.
Additionally, methacholine-induced production of NO from arterial strips, assessed using
amperometric sensors, was attenuated in OZR versus LZR (Panel B), although chronic
ingestion of SIM or ATOR increased NO production in response to challenge with
methacholine in OZR.
Data describing arteriolar constrictor responses in vessels from LZR and OZR
following challenge with phenylephrine under the conditions of the present study are
summarized in Figure 5. At 7 (Panel A) and 10 (Panel C) weeks of age, challenge with
increasing concentrations of phenylephrine produced similar arteriolar constrictor response
in OZR versus LZR under control conditions, and this relationship was not impacted by any
of the anti-cholesterol therapies. Further, inhibition of eNOS enzymes with L-NAME had no
impact on these responses at either 7 weeks (Panel B) or 10 weeks (Panel D) of age.
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However, by 13 weeks of age, OZR began to exhibit an increased constrictor response to
phenylephrine (Panel E), and this effect was even more pronounced at 17 weeks of age
(Panel G). This increased constrictor response was largely unaltered by chronic treatment
with GEM or PRO at either age, although chronic treatment with SIM and ATOR blunted
the augmentation to phenylephrine-induced constriction with age in OZR. Acute inhibition
of eNOS with L-NAME had no effect on the differences in phenylephrine-induced
constriction at 13 (Panel F) and 17 (Panel H) weeks of age between LZR and OZR under
control conditions or following chronic treatment with GEM, but attenuated the impact of
SIM and ATOR on moderating the increased adrenergic reactivity in OZR with age. Acute
application of phentolamine (10-5 M) abolished all arteriolar responses to phenylephrine
(data not shown).
Data describing the changes in plasma markers of inflammation across groups are
summarized in Table 2. As compared to marker concentration in LZR, OZR demonstrated
significant elevations in plasma concentrations of IL-1β, IL-6, IL-10, TNF-α, RANTES,
MCP-1 and VEGF between 7 and 17 weeks of age. In general, GEM treatment had a
minimal impact on these relationships in OZR, regardless of animal age, and PRO
treatment reduced the elevation in RANTES (regulated upon activation normal T-cell
expressed and secreted) at 17 weeks only. In contrast, treatment of OZR with SIM or
ATOR altered levels of all markers by 13 weeks of age, except VEGF, such that their
plasma concentration was significantly different from that in OZR under control conditions.
Regardless of treatment, plasma concentrations of VEGF were elevated in OZR versus
LZR.
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Figure 6 summarizes data from 17 week old animals from all experimental groups
correlating gastrocnemius muscle microvessel density with plasma total cholesterol (Panel
A) or vascular NO bioavailability (Panel B), with values from individual animals being
presented.

As evident from Panel A, plasma total cholesterol is a poor predictor of

rarefaction and does not effectively explain the variability in muscle vascularity in the
present study. In contrast, NO bioavailability, estimated from the magnitude of the upper
bound from the three parameter logistic equation describing the acetylcholine
concentration-response curve for individual arterioles, was a much stronger predictor of
muscle vascularity, as this parameter explained almost 81% of the variability in vessel
density in the present study.

This relationship is evident at other ages as well (data not

shown).
Table 3 presents the results of stepwise discriminant analysis based on
inflammatory marker data across the experimental groups. These analyses suggest that,
while most measured markers of inflammation were well correlated with microvessel
density and NO bioavailability, IL-10 and MCP-1 were consistent contributors to differences
not only across the experimental groups, but also over time within individual groups. In
contrast, plasma RANTES levels became increasingly significant with time in terms of
discriminating between groups. Alternatively, plasma TNF-α, demonstrated an inverse
relationship, become less significant with time, to the point where it dropped out of the
model entirely. These data are presented graphically in Figure 7. Plasma levels of VEGF,
IL-6 and IL-1β, while well correlated with microvessel density based on univariate analyses
did not contribute to the ability to discriminate between groups, and as such are not
presented in Table 3.
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The relationships between these identified markers, NO bioavailability and
microvessel density between 17 week old LZR and OZR is presented in Figure 8.
RANTES (Panel A), IL-10 (Panel B), MCP-1 (Panel C), and TNF-α (Panel D) all
demonstrate a strong correlation with NO bioavailability and microvessel density across the
animal groups.

DISCUSSION
As a contributing component to the metabolic syndrome, OZR develop moderate
hypercholesterolemia, in addition to other co-morbidities associated with this multipathology state. While previous studies have suggested that elevated plasma cholesterol
can be associated with reduced capillary density (7, 42) and blunted angiogenic responses
(36, 45), it is presently unclear as to the contribution of inflammatory status in terms of
mediating these effects. Given this, the present study was designed to chronically treat
OZR with multiple mechanistically distinct anti-cholesterol therapies throughout the period
in which microvessel loss is established to better distinguish the role for plasma cholesterol
in terms of its contribution to skeletal muscle microvascular rarefaction, and the role of
chronic inflammation in this process.
The most immediate observation of the current study was that treatment of OZR
with

the

anti-cholesterol

agents

all

resulted

in

a

comparable

reduction

in

hypercholesterolemia at each age, despite mechanistically divergent routes of action.
Probucol lowers cholesterol by increasing the fractional rate of LDL catabolism in the
metabolic pathway for cholesterol elimination from the body, and may inhibit early
stages of cholesterol biosynthesis (24). Gemfibrozil, a fibric acid derivative, is a PPARα
agonist and can reduce plasma LDL through multiple routes, including cholesteryl ester
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transfer protein activity, an increased binding affinity of LDL to its receptors, and an
increased expression of hepatic LDL receptors (24). Atorvastatin and simvastatin are
HMG CoA reductase inhibitors, and as such exert their anti-cholesterol actions via an
inhibition of this rate limiting step in cholesterol biosynthesis. This inhibition of hepatic
cholesterologenesis results in an increased expression of hepatic LDL receptors, and
leads to lowered circulating cholesterol levels (24, 27).
Although each of these therapies was comparable in terms of efficacy in reducing
plasma total cholesterol, considerable divergence was evident for their ability to
ameliorate microvascular rarefaction and improve arteriolar reactivity. From a structural
perspective, despite reductions in total cholesterol, treatment with gemfibrozil (and to a
lesser extent probucol) had a minimal impact on blunting microvascular rarefaction with
age in OZR. In contrast, chronic statin therapy lessened the severity of rarefaction,
such that microvessel density assumed a level that, although reduced from LZR, was
consistently improved versus untreated OZR.

This observation is intriguing in that

recent studies have identified a biphasic, lipid-independent, effect of chronic statin
therapy on microvessel density. Specifically, it may be that low-dose statin therapy is
associated with a “pro-angiogenic” environment through activation of Akt and increased
NO bioavailability, whereas higher statin doses can cause angiostatic effects which are
potentially mediated through a decreased protein prenylation and an inhibition of cell
growth (4, 37, 39, 49). With regard to mechanics of the microvessel wall in OZR, an
ameliorative effect was also identified, as the severe reduction in wall distensibility in
OZR was modestly attenuated as a result of chronic ingestion of atorvastatin or
simvastatin, with lesser impacts from probucol or gemfibrozil. These results support
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those determined previously, as statin therapy has been effective in reducing wall
stiffness in hypercholesterolemia (38, 40), although additional studies have suggested
that this effect may be independent of lipid profiles (44), and may better represent the
pleiotropic effects of statins on endothelial function or inflammatory status.
In our previous studies, we have provided evidence suggesting one of the main
causative mechanisms associated with microvascular rarefaction in OZR may be a
chronic reduction in vascular NO bioavailability (16). The present results support this
hypothesis, as both vascular reactivity to acetylcholine (Figure 3) and methacholineinduced NO production (Figure 4) were improved with statin therapy in OZR. Further,
when data from an age cohort of animals are summarized, an index of vascular NO
bioavailability (upper bound of the acetylcholine concentration-dilator response
relationship) was a strong predictor of gastrocnemius muscle microvessel density
(Figure 6).
The increased vascular NO bioavailability as a result of chronic atorvastatin or
simvastatin treatment was also evident with regard to phenylephrine-induced constrictor
reactivity. Specifically, the increased constrictor response of arterioles of OZR (versus
LZR) in response to adrenergic stimulation was not impacted by chronic anti-cholesterol
therapy with gemfibrozil. However, chronic treatment of OZR with atorvastatin, simvastatin
or probucol blunted the upper bound of this response, although responses were still
increased versus those in LZR. This may have been due to an increased vascular NO
bioavailability, as acute application of L-NAME, while having minimal impact on
phenylephrine-induced arteriolar constriction in OZR (±gemfibrozil), increased the upper
bound of this relationship in OZR treated with either of the other three agents.
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These data

clearly suggest that chronic treatment with anti-cholesterol agents of the “statin” family will
increase the vascular NO bioavailability (and reduce vascular oxidant stress) in OZR, and
that this relationship can impact both vascular reactivity (both dilator and constrictor) and
microvascular network structure.
One of the profound implications for hypercholesterolemia is the genesis of an
elevated state of inflammation (8, 29, 30), that can be associated with evolution of
peripheral

vasculopathy

(34,

41,

46).

While

inherent

in

the

treatment

of

hypercholesterolemia is a reduction of plasma cholesterol, amelioration of inflammation,
and improved outcomes, a key observation from the present study was that although each
treatment was effective in reducing cholesterol in OZR, there was a considerable disparity
in terms of these other processes. In the OZR model of the metabolic syndrome, we (13)
and others (1, 33) have clearly demonstrated an elevated state of inflammation and that
specific markers of inflammation can be strongly correlated with vascular outcomes
(positively or negatively, depending on marker and outcome). As the metabolic syndrome
is, by definition, composed of multiple pro-inflammatory pathologies (8), changes in
multiple markers of inflammation between groups were each significant (Table 2). Further,
given that indices of microvascular dysfunction were also tightly associated with animal
group, as well as NO bioavailability and inflammatory state severity, significant correlations
were also determined between individual markers of inflammation and specific indices of
vascular dysfunction.

While interesting from a conceptual standpoint, these results are

largely uninformative with respect to evaluating mechanistic bases of inflammation-induced
vascular dysfunction in OZR. Further, additional insight cannot effectively be gleaned from
multivariate regression techniques, as the independent variables (i.e., markers of
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inflammation) demonstrate a greater co-linearity amongst themselves than with an
outcome (e.g., microvessel density).
As a result, we incorporated the use of discriminant analyses (Figure 7 and Table
3), a classification technique for evaluating how multiple variables contribute to
differences between experimental groups and one which is specifically designed for
accurate hypothesis development. These analyses result in a rank ordering of ceteris
paribus correlation coefficients in terms of significance for the establishment of
differences between groups.

The beneficial impact of discriminant analyses is that

through a series of iterations, we are able to identify which parameters are most
significant, and also which parameters are significant only because they operate
through the magnitude of others.

As an example, while results from ANOVA or

regression suggest that IL-1β or IL-6 are correlated with low NO bioavailability, they
suffer from considerably co-linearity with other predictive markers, limiting their utility. In
contrast, discriminant analyses suggests that these markers may be less important than
RANTES, MCP-1, IL-10, and TNF-α, and may not directly contribute to differences
between LZR and OZR under control conditions and following chronic anti-cholesterol
therapy. These parameters identified from discriminant analyses can be used for the
more targeted model development and future hypothesis testing.

It is important to

emphasize that these procedures do not result in an identification of the four key
markers contributing to vasculopathy in the metabolic syndrome. Rather, given the
limited data set employed in the present study, these analyses indicate how four
markers, each of which demonstrates a strong univariate association with the vascular
outcomes vary over time in terms of their ability to discriminate an outcome between

108

experimental groups. With ongoing study and the inclusion of additional discriminating
elements, the results of these procedures will change, although the ultimate goal is the
convergence on a more stable predictive model with increasing iterations.
One of the interesting observations of the present study was while chronic
treatment with the anti-cholesterol agents reduced total cholesterol in OZR to levels that
were comparable to that in LZR, treatment with either of the two statin medications had
the additional benefit of also reducing mean arterial pressure and improving glycemic
control (i.e., insulin sensitivity) as well as providing a modest lowering of the
hypertriglyceridemia in OZR. Given that the statin medications were also the most
effective in terms of improving microvascular outcomes in the present study, it may be
that the combination of these associated beneficial impacts of statin therapy on the
other contributing pathologies of the metabolic syndrome in OZR also represented
substantial mediators of the improvement to microvascular function.

While an

appealing possibility, the current data only allow for speculation on this hypothesis, as
additional control experiments would be required to evaluate the role for these additional
elements.

However, this is an area of investigation that may warrant additional

investment.
In summary, while development of moderate hypercholesterolemia in OZR is
associated with impaired microvascular function, chronic treatment of elevated
cholesterol levels does not per se result in a significant improvement to poor outcomes.
Rather, only anti-cholesterol treatments that improved vascular NO bioavailability and
attenuated the chronic inflammation in OZR (statins) were successful in improving
microvascular and perfusion outcomes, suggesting that total plasma cholesterol itself
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may be a poor predictor of vascular outcomes in this model. Chronic inflammation,
when combined with vascular NO bioavailability, may be far stronger than total
cholesterol as a predictor of vascular dysfunction, and the implementation of
discriminant analyses for changes to the inflammatory profile may reflect a more
informative means through which future experiments may be designed.

110

Reference List

1. Barbato, J.E., B.S. Zuckerbraun, M. Overhaus, K.G. Raman and E. Tzeng. Nitric
oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance
and the metabolic syndrome. Am J Physiol Heart Circ Physiol. 289:H228-236, 2005.
2. Baumbach, G.L. and M.A. Hajdu.

Mechanics and composition of cerebral

arterioles in renal and spontaneously hypertensive rats. Hypertension. 21:816-826,
1993.
3. Beckman, J.A. and M.A. Creager. The nonlipid effects of statins on endothelial
function. Trends Cardiovasc Med. 16:156-162, 2006.
4. Boodhwani, M., Y. Nakai, P. Voisine, J. Feng, J. Li, S. Mieno, B. Ramlawi, C.
Bianchi, R. Laham and F.W. Sellke.

High-dose atorvastatin improves

hypercholesterolemic coronary endothelial dysfunction without improving the
angiogenic response. Circulation. 114:I402-I408, 2006.
5. Bray, G.A. The Zucker-fatty rat: a review. Fed Proc. 36:148-153, 1977.
6. Brzezinska, A.K., D. Gebremedhin, W.M. Chilian, B. Kalyanaraman and S.J.
Elliott.

Peroxynitrite reversibly inhibits Ca(2+)-activated K(+) channels in rat

cerebral artery smooth muscle cells. Am J Physiol Heart Circ Physiol. 278:H1883H1890, 2000.
7. Bucay, M., J. Nguy, R. Barrios, C.H. Chen and P.D. Henry. Impaired adaptive
vascular growth in hypercholesterolemic rabbit. Atherosclerosis. 139:243-251, 1998.

111

8. Dandona, P., A. Aljada, A. Chaudhuri, P. Mohanty and R. Garg.

Metabolic

syndrome: a comprehensive perspective based on interactions between obesity,
diabetes, and inflammation. Circulation. 111:1448-1454, 2005.
9. Davidson, M.H., L. Ose, J. Frohlich, R.S. Scott, C.A. Dujovne, I.D. Escobar, M.C.
Bertolami, F. Cihon, D.L. Maccubbin, M. Mercuri.
simvastatin

and

atorvastatin

on

high-density

Differential effects of

lipoprotein

cholesterol

and

apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Clin Cardiol. 26:509-514, 2003.
10. Duarte, J., A. Martinez, A. Bermejo, B. Vera, M.J. Gamez, P. Cabo and A.
Zarzuelo. Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur
J Pharmacol. 365:225-232, 1999.
11. Endres, M.

Statins: potential new indications in inflammatory conditions.

Atheroscler Suppl. 7:31-35, 2006.
12. Field, K.M.

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

on high-sensitivity C-reactive protein levels. Pharmacotherapy. 25:1365-1377, 2005.
13. Frisbee, J.C., J. Balch Samora, J. Peterson and R. Bryner. Exercise training
blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ
Physiol. 291:H2483-H2492, 2006.
14. Frisbee, J.C. Impaired hemorrhage tolerance in the obese Zucker rat model of
metabolic syndrome. J Appl Physiol. 100:465-473, 2006.
15. Frisbee JC. Vascular adrenergic tone and structural narrowing constrain reactive
hyperemia in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol.
290:H2066-H2074, 2006.

112

16. Frisbee, J.C.

Reduced nitric oxide bioavailability contributes to skeletal muscle

microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp
Physiol. 289:R307-R316, 2005.
17. Frisbee, J.C.

Hypertension-independent microvascular rarefaction in the obese

Zucker rat model of the metabolic syndrome. Microcirculation. 12:383-392, 2005.
18. Frisbee, J.C.

Enhanced arteriolar alpha-adrenergic constriction impairs dilator

responses and skeletal muscle perfusion in obese Zucker rats. J Appl Physiol.
97:764-772, 2004.
19. Frisbee, J.C.

Impaired skeletal muscle perfusion in obese Zucker rats. Am J

Physiol Regul Integr Comp Physiol. 285:R1124-R1134, 2003.
20. Frisbee, J.C.

Remodeling of the skeletal muscle microcirculation increases

resistance to perfusion in obese Zucker rats. Am J Physiol Heart Circ Physiol.
285:H104-H111, 2003.
21. Ginsberg, H.N. Efficacy and mechanisms of action of statins in the treatment of
diabetic dyslipidemia. J Clin Endocrinol Metab. 91:383-392, 2006.
22. Greene, A.S., J.H. Lombard, A.W. Cowley Jr and F.M. Hansen-Smith.
Microvessel changes in hypertension measured by Griffonia simplicifolia I lectin.
Hypertension. 15:779-783, 1990.
23. Guerre-Millo, M. Regulation of ob gene and overexpression in obesity. Biomed
Pharmacother. 51:318-323, 1997.
24. Hardman, J.G., L.E. Limbird and A.G. Gilman (Eds.). “Goodman and Gilman’s:
The Pharmacological Basis of Therapeutics” 10th edition, McGraw-Hill, Inc., New
York, NY. 2001, pp. 971-1002.

113

25. Hognestad, A., P. Aukrust, R. Wergeland, O. Stokke, L. Gullestad, A.G. Semb,
T. Holm, A.K. Andreassen and J.K. Kjekshus.

Effects of conventional and

aggressive statin treatment on markers of endothelial function and inflammation. Clin
Cardiol. 27:199-203, 2004.
26. John, S., C. Delles, J. Jacobi, M.P. Schlaich, M. Schneider, G. Schmitz, R.E.
Schmieder.

Rapid improvement of nitric oxide bioavailability after lipid-lowering

therapy with cerivastatin within two weeks. J Am Coll Cardiol. 37:1351-1358, 2001.
27. Knopp, R.H. and P. Paramsothy. Treatment of hypercholesterolemia in patients
with metabolic syndrome: how do different statins compare? Nat Clin Pract
Endocrinol Metab. 2:136-137, 2006.
28. Laufs, U., V. La Fata, J. Plutzky and J.K. Liao. Upregulation of endothelial nitric
oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1129-1135, 1998.
29. Libby, P. Inflammation in atherosclerosis. Nature. 420:868-874, 2002.
30. Lyon, C.J., R.E. Law and W.A. Hsueh. Minireview: adiposity, inflammation, and
atherogenesis. Endocrinology. 144:2195-2200, 2003.
31. Martinez-Gonzalez, J., J. Alfon, M. Berrozpe and L. Badimon.

HMG-CoA

reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in
early lesions from hypercholesterolemic swine independently of their effect on
plasma cholesterol levels. Atherosclerosis. 159:27-33, 2001.
32. Mason, R.P., M.F. Walter, C.A Day and R.F. Jacob. Intermolecular differences of
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct
pharmacologic and pleiotropic actions. Am J Cardiol. 96:11F-23F, 2005.

114

33. Picchi, A., X. Gao, S. Belmadani, B.J. Potter, M. Focardi, W.M. Chilian and C.
Zhang.

Tumor necrosis factor-alpha induces endothelial dysfunction in the

prediabetic metabolic syndrome. Circ Res. 99:69-77, 2006.
34. Pirro, M., G. Schillaci, G. Savarese, F. Gemelli, G. Vaudo, D. Siepi, F. Bagaglia
and E. Mannarino. Low-grade systemic inflammation impairs arterial stiffness in
newly diagnosed hypercholesterolaemia. Eur J Clin Invest. 34:335-341, 2004.
35. Ray, K.K. and C.P. Cannon.

The potential relevance of the multiple lipid-

independent (pleiotropic) effects of statins in the management of acute coronary
syndromes. J Am Coll Cardiol. 46:1425-1433, 2005.
36. Sasaki, K., J. Duan, T. Murohara, H. Ikeda, S. Shintani, T. Shimada, T. Akita, K.
Egami and T. Imaizumi. Rescue of hypercholesterolemia-related impairment of
angiogenesis by oral folate supplementation. J Am Coll Cardiol. 42:364-372, 2003.
37. Sata, M., H. Nishimatsu, J. Osuga, K. Tanaka, N. Ishizaka, S. Ishibashi, Y.
Hirata and R. Nagai.

Statins augment collateral growth in response to ischemia

but they do not promote cancer and atherosclerosis. Hypertension. 43:1214-1220,
2004.
38. Shige, H., A. Dart and P. Nestel. Simvastatin improves arterial compliance in the
lower limb but not in the aorta. Atherosclerosis. 155:245-250, 2001.
39. Skaletz-Rorowski, A. and K. Walsh.

Statin therapy and angiogenesis. Curr Opin

Lipidol. 14:599-603, 2003.
40. Smilde, T.J., F.W. van den Berkmortel, H. Wollersheim, H. van Langen, J.J.
Kastelein and A.F. Stalenhoef.

The effect of cholesterol lowering on carotid and

115

femoral

artery

wall

stiffness

and

thickness

in

patients

with

familial

hypercholesterolaemia. Eur J Clin Invest. 30:473-480, 2000.
41. Stokes, K.Y.

Microvascular responses to hypercholesterolemia: the interactions

between innate and adaptive immune responses. Antioxid Redox Signal. 8:11411151, 2006.
42. Theilmeier G, Verhamme P, Dymarkowski S, Beck H, Bernar H, Lox M,
Janssens S, Herregods MC, Verbeken E, Collen D, Plate K, Flameng W,
Holvoet P.

Hypercholesterolemia in minipigs impairs left ventricular response to

stress: association with decreased coronary flow reserve and reduced capillary
density. Circulation. 106:1140-1146, 2002.
43. Tofovic, S.P. and E.K. Jackson. Rat models of the metabolic syndrome. Methods
Mol Med. 86:29-46, 2003.
44. Ubels, F.L., J.H. Muntinga, J.J. van Doormaal, W.D. Reitsma and A.J. Smit.
Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics.
Atherosclerosis. 154:155-161, 2001.
45. Van Belle, E., A. Rivard, D. Chen, M. Silver, S. Bunting, N. Ferrara, J.F. Symes,
C. Bauters and J.M. Isner. Hypercholesterolemia attenuates angiogenesis but does
not preclude augmentation by angiogenic cytokines. Circulation. 96:2667-2674,
1997.
46. van Haelst, P.L., J.J. van Doormaal, F.W. Asselbergs, A.M. van Roon, N.J.
Veeger, M.M. Henneman, A.J. Smit, J.W. Tervaert, J.F. May and R.O. Gans.
Correlates of endothelial function and their relationship with inflammation in patients
with familial hypercholesterolaemia. Clin Sci (Lond). 104:627-632, 2003.

116

47. Vaziri, N.D., Z.G. Xu, A. Shahkarami, K.T. Huang, B. Rodriguez-Iturbe and R.
Natarajan. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP
kinase, and matrix expressions in obesity. Kidney Int. 68:2787-2793, 2005.
48. Walker, A.B., P.D. Chattington, R.E. Buckingham and G. Williams.

The

thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects
against impairment of endothelial function in Zucker fatty rats. Diabetes. 48:14481453, 1999.
49. Weis, M., C. Heeschen, A.J. Glassford and J.P. Cooke. Statins have biphasic
effects on angiogenesis. Circulation. 105:739-745, 2002.
50. Xiang, L., J.S. Naik, S.R. Abram and R.L. Hester. Chronic hyperglycemia impairs
functional

vasodilation

via

increasing

thromboxane

receptor-mediated

vasoconstriction. Am J Physiol Heart Circ Physiol. [Epub ahead of print], 2006.
51. Xiang, L., J.S. Naik, B.L. Hodnett and R.L. Hester. Altered arachidonic acid
metabolism impairs functional vasodilation in metabolic syndrome. Am J Physiol
Regul Integr Comp Physiol. 290:R134-R138, 2006.
52. Xiang, L., J. Naik and R.L. Hester. Exercise-induced increase in skeletal muscle
vasodilatory responses in obese Zucker rats. Am J Physiol Regul Integr Comp
Physiol. 288:R987-R991, 2005.
53. Zhou, Z., E. Rahme and L. Pilote. Are statins created equal? Evidence from
randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular
disease prevention. Am Heart J. 151:273-281, 2006.

117

Table 1. Characteristics of animal groups within the present study. * p<0.05 vs. LZR; †
p<0.05 vs. OZR.

Mass (g)

MAP (mmHg)

Glucose (mg/dl)

Insulin (ng/ml)

Chol (mg/dl)

TG (mg/dl)

N-tyrosine (ng/ml)

Age

LZR

OZR

OZR-GEM

OZR-PRO

OZR-SIM

OZR-ATOR

7w

155±5

241±6*

254±8*

250±9*

247±8*

245±5*

10w

238±6

401±8*

398±7*

400±9*

405±8*

408±7*

13w

304±7

513±10*

520±10*

508±12*

506±9*

501±8*

17w

369±5

628±12*

630±12*

625±13*

622±12*

618±9*

7w

98±4

95±5

97±5

98±6

93±5

99±4

10w

99±5

99±5

102±6

100±5

99±4

100±5

13w

102±5

112±6

115±6

112±8

102±6

104±6

17w

102±4

129±5*

127±5*

123±4*

118±4*

113±5*†

7w

93±7

98±4

104±7

102±8

96±8

93±6

10w

96±6

103±7

105±8

104±9

101±9

105±8

13w

99±7

123±8*

128±8*

128±8*

128±6*

121±8*

17w

106±9

168±10*

170±8*

169±11*

150±7*

155±8*

7w

1.0±0.3

3.2±0.5*

4.1±0.6*

3.6±0.7*

2.9±0.5*

3.0±0.6*

10w

1.1±0.2

4.9±0.7*

5.4±0.6*

6.0±0.6*

4.8±0.6*

4.3±0.5*

13w

1.2±0.3

7.9±0.6*

7.5±0.7*

7.8±0.8*

6.0±0.6*

5.7±0.6*

17w

1.2±0.2

9.0±0.8*

8.2±0.6*

9.1±0.9*

6.4±0.8*†

6.5±0.6*†

7w

80±7

98±8

95±10

95±9

91±9

94±6

10w

82±6

106±7*

84±8†

83±9†

83±8†

84±7†

13w

77±8

128±10*

87±9†

88±9†

85±9†

85±9†

17w

71±10

142±12*

86±9†

84±11†

82±11†

81±12†

7w

101±8

175±9*

178±12*

176±10*

180±11*

176±11*

10w

106±7

247±11*

249±14*

255±14*

252±12*

258±14*

13w

124±10

341±12*

338±11*

338±13*

290±14*†

302±13*†

17w

140±12

360±15*

342±20*

330±14*†

320±15*†

316±16*†

7w

9±2

16±4

17±4

12±4

13±4

14±3

10w

11±3

25±4*

26±4*

20±3*

16±4

15±5

13w

12±3

49±7*

45±7*

30±6*†

24±5*

25±4*†

17w

12±3

61±6*

53±5*

40±5*†

29±5*†

27±5*†
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Table 2. Plasma markers of inflammation (pg/ml) in the present study. * p<0.05 vs. LZR;
† p<0.05 vs. OZR.

IL-1β

IL-6

IL-10

TNF-α

RANTES

MCP-1

VEGF

Age

LZR

OZR

OZR-GEM

OZR-PRO

OZR-SIM

OZR-ATOR

7w

9.2±0.7

9.4±0.6

9.1±0.8

8.5±1.0

8.5±0.8

8.4±0.5

10w

9.4±0.6

13.4±1.8*

12.2±1.6*

12.6±1.8*

11.0±1.4*

10.8±1.1*

13w

9.8±0.7

18.5±2.0*

18.3±1.9*

16.8±1.7*

12.0±1.9*†

12.2±1.8*†

17w

10.2±0.8

23.2±2.5*

19.8±2.2*

18.5±2.0*

14.4±1.8†

15.0±2.0†

7w

26.2±4.8

35.5±5.1

33.8±4.6

29.8±5.3

28.0±4.5

31.1±4.4

10w

30.8±5.4

40.5±5.4

36.2±6.0

34.3±5.5

29.9±4.3

35.0±5.1

13w

36.8±5.6

68.6±6.1*

65.2±5.6*

64.6±5.8*

38.4±6.1†

40.6±4.6†

17w

38.6±4.6

79.8±5.7*

77.2±6.6*

71.0±6.4*

52.4±5.8†

53.9±6.1†

7w

14.6±2.6

24.8±4.0

22.0±4.1

16.5±3.8

15.2±3.8

14.6±3.1

10w

15.2±3.6

80.3±6.7*

75.3±8.0*

64.4±9.0*

51.0±6.8*†

49.5±5.8†

13w

16.4±3.7

116.4±10.5*

108.8±10.4*

104.3±8.9*

68.5±7.6*†

62.4±6.8*†

17w

18.4±3.0

124±11.5*

117.4±10.4*

114.4±12.0*

74.4±9.4*†

68.8±11.2*†

7w

2.0±0.4

5.0±1.0*

5.1±0.9*

4.6±0.7*

3.9±0.7*

3.5±0.6*

10w

2.5±0.4

8.9±1.0*

8.4±1.1*

7.2±1.2*

5.8±0.8*†

6.3±1.1*†

13w

3.2±0.3

10.3±1.6*

9.8±0.9*

8.6±1.8*

5.0±1.2†

5.7±1.6†

17w

3.4±0.4

10.4±1.4*

10.8±1.2*

8.8±1.5*

6.2±1.4†

6.8±1.6†

7w

28.0±4.7

34.2±4.8

35.0±5.1

33.4±4.9

31.3±5.5

29.6±4.6

10w

32.2±4.6

66.6±7.9*

60.4±8.2*

53.4±5.3*

43.4±5.8†

44.2±4.7†

13w

36.4±4.8

120.2±10.3*

117.4±9.9*

108.8±10.9*

85.4±9.9*†

80.8±7.9*†

17w

40.1±5.3

187.2±14.1*

176.8±15.8*

138.4±14.8*†

97.8±14.0*†

102.8±13.6*†

7w

36.6±5.8

45.0±5.9

43.8±5.2

45.6±4.9

40.4±5.1

41.2±6.0

10w

36.8±4.7

57.7±10.5

54.9±12.0

51.5±6.4

43.6±5.2*†

42.5±5.0*

13w

42.1±4.6

98.4±10.4*

95.6±10.6*

81.0±8.9*

66.4±9.4*†

62.2±6.3*†

17w

42.2±5.8

120.2±10.8*

118.4±12.0*

116.6±14.2*

80.4±12.1*†

77.8±11.4*†

7w

35.6±5.0

39.6±6.1

37.0±4.6

40.2±4.5

38.3±4.3

39.6±5.3

10w

41.1±5.3

55.5±4.5*

56.2±4.8*

50.2±5.3*

53.4±4.9*

55.5±4.5*

13w

39.2±5.3

62.9±6.7*

60.6±5.7*

58.6±6.1*

54.6±5.1*

56.9±6.4*

17w

38.9±4.1

68.7±5.4*

66.2±6.1*

61.8±5.8*

57.4±4.5*

58.8±4.8*
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Table 3.

Structure matrix of results from discriminant analyses for markers of

inflammation between animal groups in the present study. * represents the largest
absolute correlation between each variable and any discriminant function.
Age

7 Weeks

10 Weeks

13 Weeks

17 Weeks

Functions

1

2

1

2

1

2

1

2

% of Variance

81.7

12.0

96.2

2.6

97.3

3.0

98.3

1.5

Canonical Correlation

0.907

0.636

0.975

0.581

0.988

0.746

0.964

0.405

RANTES

---

---

0.364

0.683*

0.504

0.289

0.647*

-0.760*

IL-10

0.390

0.700*

0.531*

-0.182

0.576*

-0.389

0.521

0.593

MCP-1

0.368

-0.049

0.384

0.428

0.465

0.568*

0.501

0.452

TNF-α

0.553*

-0.568

0.401

-0.173

0.244

-0.300

---

---
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FIGURE LEGENDS
Figure 1. Data (mean±SEM) microvessel density within skeletal muscle of LZR and OZR
at 7 weeks (Panel A), 10 weeks (Panel B), 13 weeks (Panel C) and 17 weeks (Panel D) of
age.

Microvessel density data are presented under control conditions and following

chronic treatment of OZR with the anti-cholesterol therapies: gemfibrozil, probucol,
simvastatin or atorvastatin.

Microvessel density was determined using fluorescence

microscopy following labeling of microvessel with Griffonia simplicifolia I lectin (please see
text for details). * p<0.05 vs. LZR; † p<0.05 vs. OZR.

Figure 2. Data (mean±SEM) describing incremental distensibility and the slope (β)
coefficients from circumferential stress versus strain relationships (inset panels) of skeletal
muscle arterioles of LZR and OZR at 7 weeks (Panel A), 10 weeks (Panel B), 13 weeks
(Panel C) and 17 weeks (Panel D) of age. Arteriolar wall mechanics data are presented
control conditions and following chronic treatment of OZR with the anti-cholesterol
therapies: gemfibrozil, probucol, simvastatin or atorvastatin. * p<0.05 vs. LZR; † p<0.05
vs. OZR.

Figure 3. Data (mean±SEM) describing skeletal muscle arteriolar dilation in response to
increasing concentrations of acetylcholine of LZR and OZR under control conditions and
following chronic treatment of OZR with gemfibrozil, probucol, simvastatin or atorvastatin.
Data area presented as paired panels, with the left panels summarizing the concentrationresponse relationship, and the right panel presenting the contribution of oxidant stress in
terms of impacting acetylcholine-induced dilation where the change in the upper bound of
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this relationship is shown following treatment of the arteriole with TEMPOL. Data are
presented for animals at 7 weeks (Panels A/B), 10 weeks (Panels C/D), 13 weeks (Panels
E/F) and 17 weeks (Panels G/H) of age. * p<0.05 vs. LZR; † p<0.05 vs. OZR.

Figure 4. Vascular eNOS activity (Panel A; presented as the % arginine conversion), and
methacholine-induced NO bioavailability (Panel B; where data present the slope of the
relationship between vascular NO production and methacholine concentration , nM/log M
methacholine) in LZR and OZR at 17 weeks of age. Data (presented as mean±SEM) are
summarized for LZR and OZR under control conditions and following chronic treatment of
OZR with gemfibrozil, probucol, simvastatin or atorvastatin.

* p<0.05 vs. LZR; † p<0.05

vs. OZR.

Figure 5. Data (mean±SEM) describing skeletal muscle arteriolar constriction in response
to increasing concentrations of phenylephrine in LZR and OZR under control conditions
and following chronic treatment of OZR with gemfibrozil, probucol, simvastatin or
atorvastatin. Data area presented as paired panels, with the left panels summarizing the
concentration-response relationship, and the right panel presenting the contribution of
vascular nitric oxide production in terms of impacting phenylephrine-induced constriction
where the change in the upper bound of this relationship is shown following treatment of
the arteriole with L-NAME. Data are presented for animals at 7 weeks (Panels A/B), 10
weeks (Panels C/D), 13 weeks (Panels E/F) and 17 weeks (Panels G/H) of age. * p<0.05
vs. LZR; † p<0.05 vs. OZR.
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Figure 6. The relation between plasma total cholesterol level (Panel A), or a proxy variable
for NO bioavailability (upper bound of the acetylcholine dose-response relationship; Panel
B), and microvessel density from the different animals in the present study. Each animal
used in the study, across the experimental groups is presented in this figure. The inset text
presents the linear regression equation that best fits these data and the degree to which
that equation explains the variability in the data.

Figure 7. Summary plot for the results of the discriminant analyses in the present study.
These results provide the functions 1 and 2 (presented in Table 3) which contribute the
majority (>90%) of the differences between the experimental groups at each age.
Specifically, RANTES, IL-10, MCP-1 and TNF-α play the greatest role in terms of
establishing differences between LZR (light blue), OZR (green), and OZR under the four
treatment conditions of the present study; gemfibrozil (grey), probucol (purple), simvastatin
(orange) and atorvastatin (red). The centroids for each group are presented in the dark
blue squares.

Figure 8. Relationships between the four most significant markers of inflammation
(identified using discriminant analyses; please see text for details), vascular NO
bioavailability, and gastrocnemius muscle microvessel density for animals in the present
study. Data are presented for RANTES (Panel A), IL-10 (Panel B), MCP-1 (Panel C), and
TNF-α (Panel D), and the same color coding is used as in Figure 4; LZR (light blue), OZR
(green), and OZR+GEM (grey), OZR+PRO (purple), OZR+SIM (orange) and OZR+ATOR
(red).
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Chapter 5
TEMPORAL PROGRESSION OF MICROVASCULAR RAREFACTION IN THE
METABOLIC SYNDROME; THE ROLE OF THROMBOXANE A2
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ABSTRACT
The metabolic syndrome represents an integrated metabolic and cardiovascular
disorder reflecting the development of multiple risk factors for a poor cardiovascular
outcome, including obesity, insulin resistance, dyslipidemia, hypertension and the
genesis of pro-inflammatory and pro-oxidant environments. The obese Zucker rat
(OZR) represents an excellent model of metabolic syndrome, and develops this
condition due to chronic hyperphagia. While impairments to vascular reactivity with
metabolic syndrome have been well established and are partly a function of reduced
nitric oxide bioavailability and altered arachidonic acid metabolism, we have made the
novel and consistent observation that reductions to skeletal muscle microvascular
density (rarefaction) also develop in parallel with reactivity alterations, and that this
plays a key contributing role in contributing to disparities between matching metabolic
demand to perfusion. While our previous publications have demonstrated that the full
extent of rarefaction is well predicted by a chronic loss of nitric oxide bioavailability, our
most recent data strongly suggest that an early pulse of rarefaction develops very
rapidly in the OZR model of metabolic syndrome which significantly precedes any
demonstrable loss in NO bioavailability. Our advanced statistical analyses have
suggested that the strongest associated parameter with the early pulse of microvascular
rarefaction is a shift in vascular arachidonic acid metabolism from prostacyclin (PGI2) to
thromboxane A2 (TxA2). Presented within this manuscript are data supporting a role for
TxA2 elevations in early rarefaction and underlying role for elevations in oxidant stress
and TNFα levels in the elevations in TxA2 production.
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INTRODUCTION
With the development and maintenance of an obese state comes the
establishment of pro-oxidant (22; 28; 32; 40), pro-thrombotic (1; 31), and proinflammatory (8; 24; 26; 35) conditions along with concurrent development of insulin
resistance (25; 34; 43), dyslipidemia (29), and hypertension (2). This constellation of an
initiating pathology of obesity along with its associated co-morbidities is clinically
classified as the “metabolic syndrome” (38). It is estimated that as many as 50 million
Americans (38) currently fit the requisite criteria for diagnosis of metabolic syndrome
with those numbers steadily increasing both nationally (7) and globally (23). While each
individual pathology associated with metabolic syndrome is significant, their greatest
impact on public health is that they dramatically increase the risk for developing
peripheral vascular disease, resulting in an imbalance between skeletal muscle demand
and adequate perfusion (12; 13; 18; 41; 42).

This imbalance in demand:perfusion

matching leads to ischemia (15), compromised tissue function (15), diminished tissue
viability(37) and quality of life issues (37).
The obese Zucker rat (OZR) serves as an established model of metabolic
syndrome, owing to a dysfunctional leptin receptor gene which results in a chronic state
of hyperphagia. These animals become rapidly obese and, in turn, develop insulin
resistance, dyslipidemia and moderate hypertension along with the pro-thrombotic, proinflammatory and pro-oxidant environment characteristic of their human metabolic
syndrome counterparts.

Previous studies by multiple investigative groups have

demonstrated negative vascular outcomes in OZRs with the development of metabolic
syndrome, including alterations to vascular wall mechanics, impairments to multiple
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indexes of dilator reactivity, alterations to signaling mechanisms underlying constrictor
reactivity, and a rarefaction of microvascular networks within multiple tissues(6; 15; 18;
19; 40; 42). The culmination of these alterations to microvascular structure and function
within OZRs can result in profound impairments to the perfusion of tissue under an
array of physiological and pathological conditions.
In recent years, studies have demonstrated that alterations to arachidonic acid
metabolism (AA) through the cyclooxygenase (COX) pathway may contribute to the
demand:perfusion disparities seen in OZRs. AA is stored in the cell membrane of most
resting cells, esterified to glycerol groups of phospholipids (9). It is released from this
“stored” esterified state when activated phospholipases (A, C or D) catalyze hydrolysis
of the phospholipid thereby allowing for AA desequestration (9). Upon release, this free
arachidonate can: be reincorporated into phospholipids, diffuse away from the cell, or
diffuse into the cell at which time it is subject to metabolism (30). The metabolism of
arachidonic acid is characterized by three major pathways: Cyclooxygenase,
Lipoxygenase and Cytochrome P450. Alterations to relative metabolism through each of
these pathways has been demonstrated to occur in a number of disease states (3-5;
33).

Recent studies have demonstrated a shift in the balance of TxA2 and PGI2

produced downstream from COX with a predomination of TxA2 production resulting in
attenuated dilator responses as the constrictor prostanoid TxA2 blunts the response of
the typically predominant COX dilator prostanoid, PGI2 (20; 36; 36; 40).
In addition to the above mentioned vasomotor dysfunction found in metabolic
syndrome, there are significant vascular network remodeling components in the skeletal
muscles of metabolic syndrome individuals and OZRs. There is a well documented and
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progressive loss of tissue capillarity in metabolic syndrome subjects termed rarefaction
(21; 27; 39). This rarefaction process while well documented, is only poorly understood.
Recent work from this lab has attributed much of the rarefactive process to diminished
NO bioavailability as therapeutics which spared NO were also able to maintain tissue
microvessel density (10; 11; 16). This study re-examines those earlier findings which
focused on tissue microvessel density during a single timepoint and attempts to
establish the progression of rarefaction as it parallels development of the metabolic
syndrome. Rather than wait for the classically employed 17-week age range wherein
OZRs are showing all major symptoms of the metabolic syndrome, this study begins at
7 weeks of age where metabolic syndrome symptoms are intermediate at best. The
novel observation of this work is that our understanding of rarefaction is not inaccurate
though it is incomplete. There does, indeed, appear to be a NO mediated phase of
rarefaction but only subsequent to an early and mechanistically distinct rarefactive
process mediated by the obesity associated shift in prostanoid production through the
COX pathway.
The purpose of the present study was to identify key contributors to the process
of obesity related skeletal muscle microvascular rarefaction in an established animal
model of the metabolic syndrome. Based on the existing data set, the hypothesis to be
tested was that metabolic syndrome mediated rarefaction is a linear process regulated
by a single major mechanism. This somewhat implausible hypothese was rapidly
disproven as studies demonstrated that the process of rarefaction is far more complex.
Rarefaction in metabolic syndrome is neither linear nor mediated by a single
mechanism.

The system is regulated by multiple, temporally and mechanistically
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distinct mechanisms with an early rarefactive pulse mediated by shifts in prostanoid
production and a later pulse mediated by diminished NO bioavailability.

MATERIALS AND METHODS:
Animals:

Male LZRs and OZRs (6-20 wks old, as indicated; 17 weeks old if not

otherwise indicated) were used for all experiments. Rats were fed standard chow and
tap water ad libitum. After an overnight fast, rats were anesthetized with injections of
pentobarbital sodium (50 mg/kg ip) and received tracheal intubation to facilitate
maintenance of a patent airway. In all rats, a carotid artery and an external jugular vein
were cannulated for the determination of arterial pressure and for the intravenous
infusion of supplemental anesthetic, if necessary. Blood was drawn from the jugular
vein to be used for the biochemical determination of plasma glucose (Freestyle, Abbott
Diabetes Care, Alameda, CA), insulin (Millipore, St. Charles, MO), and measurements
for TNFα (Millipore, St. Charles MO) as well as a plasma lipid profile (Stanbio, Boerne,
TX) and nitrotyrosine (Oxis, Foster City, CA) from each animal. Chronic TNFα inhibition
was accomplished in a subset of these animals through daily i.p. injection of the TNFα
inhibitor pentoxifylline [30mg/kg/day].

In additional subsets of animals oxidant

scavenging was achieved through the use of the membrane permeable superoxide
-3

dismutase mimetic 1-Oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (TEMPOL) [10 M in
drinking water]. In all animals, water consumption was monitored daily to assure that
dosing was within expected parameters.
Histological Determination of Microvessel Density: With the rat under anesthesia,
the right gastrocnemius muscle was removed, rinsed in PSS, and lightly fixed in 1%
formalin. Muscles were then embedded in paraffin and cut into 5-μm cross sections, and
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stained for Griffonia simplicifolia I lectin (Sigma). From each gastrocnemius muscle, six
randomly selected individual cross sections were used for analysis, with six randomly
selected regions within an individual cross section chosen for study. Each region of
5

2

study had an area of ~1.47 X 10 μm . After staining, sections were rinsed three times
in PSS and mounted on microscope slides with a water-soluble mounting medium (SP,
ACCU-MOUNT 280, Baxter). With the use of epifluorescence microscopy, localization
of lectin stained microvessels was performed with a Nikon Eclipse 80i upright
microscope with a X20 objective lens (Plan Fluo phase, numerical aperture 0.5).
Excitation was provided by a 75-W xenon arc lamp through a Lambda 10-2 optical filter
changer (Sutter Instruments; Novato, CA) controlling a 595-nm excitation filter and 615nm emission filter. The microscope is coupled to a cooled charge-coupled device
camera (Photometrics CoolSNAP ES).
Determination of Vascular TxA Production: Vascular production of 11-dehydro2

thromboxane B [the stable plasma breakdown product of TxA ] was assessed using
2

2

pooled conduit arteries (femoral, saphenous, and iliac arteries) from LZRs and OZRs
(treated & control). Pooled vessels from each animal were incubated in microcentrifuge
tubes in 1 ml PSS for 30 min under control conditions (21% O ) at room temperature
2

-5

and stimulated with an addition of exogenous arachidonic acid (10 M). After the 30-min
period, this PSS was transferred to a fresh tube, frozen in liquid N , and stored at -80°C.
2

Metabolite release by the vessels was determined using commercially available EIA kits
for 11-dehydro-TxB (Cayman Chemicals).
2
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Determination of Vascular Nitric Oxide Bioavailability: From each animal, the
abdominal aorta was removed and vascular NO production was assessed using
amperometric sensors (World Precision Instruments). Briefly, aortae were isolated,
sectioned longitudinally, pinned in a silastic coated dish, and superfused with warmed
(37◦C) PSS equilibrated with 95% O2 and 5% CO2. The NO sensor (ISO-NOPF 100)
was placed in close apposition to the endothelial surface and a baseline level of current
was obtained. Subsequently, increasing concentrations of methacholine (10

−10

−6

–10

M)

were added to the bath and the changes in current were determined. To verify that the
recorded data represented endothelium-dependent NO release, responses were
−4

reevaluated following acute treatment of the aortae with L-NAME (10 M).
Statistical Analyses: As this work is preliminary, each group contains 3-4 animals. As
such, the study is too insufficiently powered to provide statistical analyses at this time.
Ongoing work will, ultimately, provide greater power allowing for the employment of
appropriate statistical methods. The notable exception to this occurs in Table 1 which
draws on a more robust data set allowing for animal groups of 8.

RESULTS
Baseline characteristics of lean and obese Zucker rats are presented in Table 1.
The OZR shows significantly increased mass as early as 6 weeks of age, when
compared to age matched lean counterparts, with the disparity in lean vs. obese mass
only becoming more pronounced with time. Additionally, by 6 weeks of age, obese
Zucker rats clearly demonstrate hyperinsulemia as well as hypertriglyceridemia. By 12
weeks of age, the obese Zucker rat additionally manifests hyperglycemia with
demonstrable hypercholesterolemia finally manifesting at 17 weeks of age.
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Owing to the fact that the obese Zucker rat demonstrates all measured metrics of
metabolic syndrome employed in this study by 17 weeks of age, initial measures of the
effects of metabolic syndrome on tissue capillarity were performed within this age
window.

Results of these analyses are demonstrated in Figure 1A which clearly

demonstrates a nearly 30% loss of microvessel density (rarefaction) when comparing
the gastrocnemius muscle microvessel density in 17 week old lean and obese Zucker
rats. Acknowledging that the metabolic syndrome is a process that develops over time
in the Zucker rat and supported by the evidence shown in Table 1, further analyses of
the temporal effects of metabolic syndrome on skeletal muscle microvessel density
were performed from 7 to 20 weeks of age in approximately 3 week iterations. The
results of these analyses, summarized in Figure 1B, demonstrate that at 7 weeks of
age, obese Zucker rats maintain normal tissue capillarity despite the elevated mass,
plasma insulin and triglyceride levels demonstrated in Table 1. However, given time,
these rats undergo a biphasic rarefactive process wherein there is an early period of
rarefaction from 7 to 10 weeks of age constituting an approximate 15% loss of
microvessel density in the gastrocnemius muscle. This early rarefaction is followed by a
plateau from 10-13 weeks of age wherein there is no apparent loss of microvessel
density.

Subsequent to the rarefactive plateau is a late phase of rarefaction

accountable for the remaining 15% loss of microvessel density. Analyses to 20 weeks
of age and beyond (data not shown) demonstrate that this capillarity remains relatively
constant through the remainder of the animal’s life.
Previous studies from this laboratory have demonstrated an inverse relationship
between vascular NO bioavailability and skeletal muscle microvessel density in the
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Zucker rat (17; 18). Since these studies were performed in the 17 week age with no
attention to the temporal contribution, and owing to the data in Figure 1B demonstrating
a biphasic phenomenon, vascular NO bioavailability was assayed across the 7 to 20
week age time-course of the study.

Figure 2A clearly demonstrates significant

impairment to vascular NO bioavailability beginning at 13 weeks of age with more
pronounced impairment at later time-points. This coincides well with late rarefaction,
while removing NO bioavailability as a likely causative agent in early rarefaction. Based
on previous work in this lab which demonstrated impairments in COX mediated
prostanoid balances in the obese Zucker rat, favoring a production of TxA2 over
prostacyclin (19), stimulated vascular production of TxA2 was measured in all time
points. Figure 2B, which summarizes the results of these analyses, demonstrates that
vascular production of 11-dehydro-thromboxane-B2, the stable breakdown product of
TxA2 is drastically elevated across the period of early rarefaction and remains so
through 20 weeks of age.
Determination of a mechanistic linkage between elevations in TxA2 production
and early rarefaction was accomplished by competitively antagonizing the TxA2
receptor, TP, with the compound SQ-29548. Figure 3A shows the results of this study
wherein early rarefaction was abolished in obese Zucker rats via treatment with SQ29548 with no apparent non-specific effects of the compound on lean control animals.
Figure 3B shows the results of an early withdrawal study where animals received SQ29548 from 6 to 13 weeks of age, however, at 13 weeks of age treatment was
discontinued.

The results of this portion of the study demonstrate that rarefaction

begins anew immediately following discontinuation of TP receptor antagonism.
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Figure 4 summarizes the data related to determining the mechanistic
underpinnings of obesity associated elevations in TxA2.

Figures 4A and 4B

demonstrate drastic elevations in systemic oxidant stress and plasma TNFα
concentrations, respectively, with increasing duration of the metabolic syndrome. In
both the case of oxidant stress and inflammation, elevations occur early and levels of
both nitrotyrosine and TNFα remain elevated through the time-course in untreated
obese Zucker rats. Elevations in oxidant stress were diminished via treatment with the
membrane permeable superoxide dismutase mimetic TEMPOL while production of
TNFα was inhibited through the use of pentoxifylline. The effects of these inhibitions on
stimulated vascular TxA2 production is summarized in Figure 4 panels C and D.
Chronic diminishment of superoxide levels resulted in an intermediate production of
TxA2 across the time-course. This same effect was seen in the case of TNFα synthesis
inhibition where chronic pentoxifylline treatment was able to maintain intermediate
levels of TxA2. The phenotypic consequences of chronic inhibition of oxidant stress
mechanisms or TNFα mediated inflammatory mechanisms are summarized in Figure 4
panels E and F. Panel E demonstrates that chronic inhibition of superoxide mediated
effects is sufficient to blunt but not abolish the rarefactive process demonstrated with
continued duration of metabolic syndrome in obese Zucker rats. In contrast, Panel F
demonstrates that inhibition of the inflammatory mediator TNFα with pentoxifylline is
sufficient to abolish rarefaction in obese Zucker rats through 17 weeks of age.

DISCUSSION
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With the development of metabolic syndrome comes the inevitable loss of ability
to match demand and perfusion in peripheral tissues (12; 14). Numerous investigations
have demonstrated that alterations to vasomotor function significantly contribute to the
inability to properly regulate perfusion into these tissues. However, even when the
influences of vasomotor alterations are systematically removed, perfusion levels still
remain impaired with increasing metabolic demand (10) . This impairment is attributed
to a bulk loss of microvessels/capillaries in these peripheral tissues, a process termed
rarefaction.
Despite the phenomenon of rarefaction being clinically and experimentally well
established, the mechanistic underpinnings of the process are poorly understood.
Previous work has demonstrated that capillary losses parallel loss in nitric oxide
bioavailability and with experimental evidence to support the rationale that the loss in
tissue capillarity is a direct result of diminished NO bioavailability (11; 18).

These

previous studies have provided tremendous insight into the mechanisms leading to
rarefaction and resulting in perfusion demand disparities but have suffered from the lack
of an adequate temporal component.
As Table 1 in this study demonstrates, the development of metabolic syndrome
occurs along a temporal continuum with some aspects preceding others by necessity.
For instance, obese Zucker rats manifest demonstrable hyperinsulemia as early as 6
weeks of age. This hyperinsulemia must, by necessity precede any notion of the animal
being a model of type II diabetes as glycemic control remains unimpaired until 12 weeks
of age. By logical extension, the fact that the animal suffers from fewer comorbities
than those found at later time-points in the disease could have significant impact on the
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effects of the metabolic syndrome on skeletal muscle microvessel density. Though this
distinction seems trivial in an animal that is able to fully manifest a metabolic syndrome
phenotype by 17 weeks of age, the implications in humans are far more significant as
development of metabolic syndrome is a much more gradual process typically taking
years or even decades to fully manifest.
The most obvious and significant finding of this study is found in Figure 1 panel B
which highlights the biphasic nature of obesity related microvascular rarefaction. Prior
to the onset of a type II diabetic phenotype, in the 7-10 week age window, a rarefactive
pulse constituting ~50% of the total microvessel loss occurs. It is not until 13 weeks of
age that a second rarefactive pulse occurs resulting in all remaining rarefaction. As this
window is subsequent to the development of diabetes at approximately 12 weeks of
age, the second rarefaction highlights the notion that as the pathologies evolve so do
the consequences of those pathologies. An admitted limitation of this study is the lack
of attempt to correct the diabetes in these animals to determine its contributions to later
rarefaction. What does become evident even in these early figures, however, is that
microvascular rarefaction in the metabolic syndrome is not the simple linear process
that it is often portrayed to be.
The logical extension of a biphasic process is that each phase may be mediated
through distinct processes. Data supporting this hypothesis are presented in Figure 2
which shows that the loss of NO bioavailability occurs in obese Zucker rats subsequent
to the early rarefactive period precluding the possibility of NO reductions being a
causative agent in the early microvessel loss. Building on data from previous studies
which demonstrated a shift in vascular prostanoid production with obesity, Figure 2
144

panel B presents the possibility of elevations in TxA2 as a causative factor in early
rarefaction. This correlative data are then further extended to demonstrate causality as
antagonism of the TxA2 signaling pathway results in total ablation of early rarefaction
(Figure 3). Perhaps more interesting was the discovery that when antagonism of the
TxA2 pathway was discontinued, rarefaction was renewed but blunted as indicated by
the diminished slope of rarefaction in 13-17 week window. While further studies are
required to determine what mediates this post-therapeutic rarefaction, the 13-17 week
blunting would strongly indicate that early TxA2 elevations are either necessary for later
rarefaction and have some sort of causative relationship to NO bioavailability reductions
or the TxA2 elevations somehow exacerbate the effects of NO bioavailability reductions
enhancing the consequence of those reductions with regards to rarefaction. Whatever
the case may be, the evidence provided by these data indicates that while the two
phases of rarefaction are mechanistically distinct, they may also be interconnected.
The final figures of this study attempt to demonstrate the cause of these
elevations in TxA2 production with obesity.

A significant consequence early in the

metabolic syndrome is the development of a pro-inflammatory and pro-oxidant
environment. As increased oxidative stress and inflammation is able to activate
numerous signaling pathways, they serve as logical targets of investigation for changes
in the production of essentially any vascular metabolite. Additionally, work from our lab
and others has implicated elevations in superoxide and TNFa, specifically, in alterations
to TxA2 production. Figure 4 clearly demonstrates that both superoxide and TNFa
elevations contribute to elevations in vascular TxA2 levels with the phenotypic
consequence of enhanced rarefaction.
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Taken together, these data demonstrate that metabolic syndrome related
microvascular rarefaction is a biphasic process in which each phase is both temporally
and mechanistically distinct. Early rarefaction is mediated by elevations in vascular
TxA2 levels whereas late rarefaction is mediated by diminished vascular NO
bioavailability. Preliminary evidence would indicate that the later phase of rarefaction is
at least partially enhanced, if not totally dependent, on early rarefactive processes.
Additionally, these early TxA2 mediated rarefactive processes are the result of
elevations in systemic oxidant stress and systemic inflammation. Taken together these
data highlight the TxA2 pathway as a target for potential future investigations into
therapeutic treatments for metabolic syndrome related skeletal muscle microvascular
rarefaction.

Additionally this study supports the idea of prophylactic treatment of

metabolic syndrome subjects with anti-inflammatory and anti-oxidant drugs as this study
provides another example of an instance where pathophysiologic elevations in either of
those two systems is deleterious to cardiovascular outcome.
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Table 1
Lean Zucker Rats
6 Weeks
9 Weeks
12 Weeks
142+8
202+10
270+11
89+4
105+4
101+5
106+14
111+10
106+14

15-17 Weeks
364+12
105+4
121+13

20 Weeks
385+13
109+6
125+14

1.4+0.4

1.2+1.1

1.0+0.5

1.5+0.6

1.4+1.0

[Triglycerides]plasma (mg/dl)

76+9

81+13

81+12

88+11

91+15

[Cholesterol]plasma (mg/dl)

67+8

69+8

71+11

74+8

84+11

15-17 Weeks
602+15*
128+6*
184+18*

20 Weeks
680+16*
129+5*
188+14*

9.4+1.4*

10.4+1.9*

Mass (g)
Mean Arterial Pressure (mmHg)
[Glucose]blood (mg/dl)
[Insulin]plasma (ng/ml)

Mass (g)
Mean Arterial Pressure (mmHg)
[Glucose]blood (mg/dl)

Obese Zucker Rats
6 Weeks
9 Weeks
12 Weeks
288+15*
401+14*
184+10*
88+5
110+5
118+4*
102+12
130+18
168+16*

[Insulin]plasma (ng/ml)

2.5+0.4*

6.9+1.1*

8.6+2.0*

[Triglycerides]plasma (mg/dl)

122+16*

168+14*

167+15*

309+15*

384+16*

74+10

85+10

107+13

128+12*

136+12*

[Cholesterol]plasma (mg/dl)
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FIGURE LEGENDS
Figure 1. Microvessel density in the gastrocnemius muscle of 17 week old (Panel A) or
temporally progressing (Panel B) lean and obese Zucker rats. Data are presented as
mean + SEM.
Figure 2. Stimulated vascular NO bioavailability (Panel A) or stimulated vascular
thromboxane B2 production (Panel B) measured with amperometric sensors or via
ELISA, respectively, as assayed in pooled conduit arteries. Data are presented as
mean + SEM.
Figure 3. Panel A shows microvessel density in the gastrocnemius muscles of lean and
obese Zucker rats receiving SQ-29548 therapies or left as untreated controls from 7-13
weeks of age. Panel B demonstrates gastrocnemius muscle microvessel density in
animals receiving the same treatment as in Panel A, with discontinuation of therapy at
13 weeks but measurement of density continuing to 20 weeks.
Figure 4. Figure 4 displays the elevations in oxidant stress as indicated by plasma
nitrotyrosine levels (Panel A) along with effects of anti-ROS therapies on stimulated
thromboxane production (Panel C) and ultimate consequence on microvessel density
(Panel E). Elevations in TNFα levels are highlighted in Panel B with the effects of antiTNFα therapies on TxB2 (Panel D) levels and microvessel density (Panel F) shown in
subsequent panels.
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Discussion
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The purpose of the studies presented within this work was to demonstrate the
global systemic consequences of alterations to AA metabolism on both the vasomotor
function and vascular network structure within the skeletal muscle of a well-established
rodent model of the metabolic syndrome.

We first sought to demonstrate that the

alterations to AA metabolism, specifically through the cyclooxygenase pathway, do
occur and that these alterations have significant consequences on the regulation of
skeletal muscle vascular tone. This was accomplished by employing a clean stimulus
for the production of prostacyclin, a COX pathway end-product, in both obese Zucker
rats and their age matched lean counterparts. This study, which is presented in chapter
2 of this document, was able to demonstrate a blunted hypoxic dilation which was
mediated exclusively by modest reductions in prostacyclin production and impressive
increases in the production of the vasoconstrictor thromboxane A2 within the vascular
endothelium. Further evidence within the same study was able to identify elevations in
vascular superoxide levels as a causative factor in the shift from a predominant
prostacyclin production induced vasodilation to a blunted vasodilation stemming from
pathophysiologic overproduction of thromboxane A2.

This phenomenon could be

blunted through treatment with a pegylated form of superoxide dismutase which
returned production of thromboxane A2 to a more physiologic level while having no
effects on prostacyclin production.

Interestingly, while the effects of enhanced

superoxide levels on prostacyclin production were non-existent, PEG-SOD treatment
was sufficient to largely restore a documented diminished sensitivity of the vessel to
prostacyclin to normal levels. Taken together, these data provided the foundational
work for investigations into metabolic syndrome related alterations in COX mediated AA
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metabolism as well as the underlying role of superoxide in this imbalance between
prostacyclin and thromboxane.
Building on this previous work, investigations were performed in murine models
of dyslipidemia, the LDLR knockout mouse and the ApoE knockout mouse. These
animals manifest only a single comorbidity of the metabolic syndrome but were
interesting as work presented in “Differential Impact of Familial Hypercholesterolemia
and Combined Hyperlipidemia on Vascular Wall and Network Remodeling in Mice” by
Stapleton et al. provided correlative data between alterations in vascular wall
mechanical responses and elevations in thromboxane A2 in these particular animal
models. This provided us with the idea that perhaps the dyslipidemia demonstrated in
metabolic syndrome, in some way led to the elevations in TxA2 and in turn the
vasomotor consequences that had been demonstrated in fully vested animal models of
the metabolic syndrome, as detailed in Chapter 2. This provided the impetus for the
investigations detailed in Chapter 3, wherein similar alterations to AA metabolism as
those found in the Zucker rat are demonstrated with a recapitulation of the significance
of enhanced ROS levels as a mediator of these alterations. Further, this manuscript
demonstrated the relative insignificance of lipoxygenase and cytochrome p450
pathways in the observed vasculopathies as treatments with inhibitors of each pathway
showed no effects on system responses.
Based on this compelling evidence in dyslipidemic mice, and in accordance with
documented vasoprotective effects of chronic statin therapies in humans and animal
models, we next set out to determine whether chronic reductions in circulating
cholesterol levels would be able to restore normal metabolism of AA via COX and, in
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turn, confer a protective effect on the vasculature with regards to vasomotor function.
This body of work is summarized in Chapter 4 and clearly demonstrates the ability of
statin therapies to protect against metabolic syndrome related vasculopathies
regardless of whether those vasculopathies were vasomotor, wall mechanical or
network structural in nature.

The most significant result of this study was the

demonstration that this protection occurs independent of any effects of the therapeutic
regimen on cholesterol levels. This was conveyed by treating animals with either statins
(HMG-CoA reductase inhibitors) thereby diminishing the biosynthesis of cholesterol or
fibrates whose effects increase the fractional clearance of LDL while also diminishing
absorption of LDL by the LDL-receptor. Table 1 within chapter 4 illustrates the ability of
all therapeutics to significantly lower plasma cholesterol levels in treated animals.
However, both the fibrates gemfibrozil and probucol failed to significantly protect against
any of the previously mentioned categories of vasculopathy as evidenced by negligible
impact of either of these therapies in any of the subsequent figures which assayed
acetylcholine mediated dilator responses, gastrocnemius muscle microvessel density
and arteriolar incremental distensibility. The key finding of this study was that only
those therapeutics that were capable of protecting against a loss of vascular NO
bioavailability were capable of conferring vasoprotective effects and these effects in
turn, appeared to be mediated by the drugs ability to attenuate chronic inflammatory
responses.
We next undertook a more thorough examination of the process of microvascular
rarefaction in the metabolic syndrome. The details of Chapter 4, along with previous
work, strongly indicated that microvascular rarefaction is mediated by the loss of
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vascular NO bioavailability and that those therapies capable of protecting against the
loss of NO bioavailability had the predictable outcome of protecting against skeletal
muscle microvascular rarefaction. It is in the experiments detailed in Chapter 5, where
we first set out to determine the time-course of microvascular rarefaction. The initial,
unexpected result of this study is shown in Figure 1B of Chapter 5 which clearly
demonstrates a biphasic rarefactive process ongoing in these animals.

The initial

hypothesis upon which this work was operating was that, microvascular rarefaction is a
linear process beginning in pre-metabolic syndrome animals with normal microvessel
density and progressing in a linear fashion through the time-course of the disease until
such time as minimum viable tissue capillarity is achieved.

The identification of a

biphasic nature to the rarefaction immediately precluded this hypothesis from
succeeding to be proven and additionally provided cause to re-evaluate the hypothesis
that microvascular rarefaction is mediated by loss of vascular NO bioavailability. It is
plausible that if a process demonstrates two temporally distinct phases, those phases
may well be mechanistically independent as well.
Investigations

into

the

mechanistic

underpinnings

of

early

rarefaction,

immediately ruled out reductions in NO bioavailability as a mediator of microvessel loss,
as stimulated vascular production of NO is indistinguishable during the time period of
early rarefaction when comparing age matched lean and obese Zucker rats. However,
late phase microvascular rarefaction demonstrated a strong and inverse relationship to
vascular NO bioavailability which, when taken with the previous data, still indicates that
the later phase of rarefaction is mediated by NO loss.

Based on the previously

established information of Chapters 2-4, there was sufficient evidence to indicate the
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possibility that altered inflammatory status and elevations in systemic oxidant stress
could be impacting COX mediated metabolism and that this alteration could have
effects on rarefaction.

The data outlined in Chapter 5 demonstrate that there are

alterations to AA metabolism that occur early in the development of the OZR, resulting
in drastic elevations in TxA2 during the period of early microvascular rarefaction.
Further, when the effects of these elevations are blocked by antagonism of the TxA2
cognate receptor TP by treatment with the competitive antagonist, SQ-29548, there is a
complete abolition of early microvascular rarefaction. This effect on early rarefaction
can be blunted through alternative pathways, as demonstrated by treatment with the
anti-TNFa synthesis compound pentoxifylline or treatment with the oxidant scavenger
TEMPOL. Both therapeutics were capable of drastically diminishing elevations in TxA2
and, by extension, early rarefaction. Finally, this study demonstrated the effects of early
withdrawl from the compound wherein animals were treated through the entire phase of
early rarefaction with the TP receptor antagonist SQ-29548 but then removed from
treatment in a fashion temporally consistent with the end of early rarefaction. What was
demonstrated was that although rarefaction began anew, this delayed rarefactive
process was diminished in intensity from the anticipated 15% rarefaction that generally
occurs with late phase rarefaction to approximately a 6% loss of total microvessel
density.
What requires the greatest scrutiny for future investigation is what mediated that
pulse of late rarefaction during the early withdrawl study.

Whether this late phase

rarefaction was still a NO mediated process or whether it was just a delayed TxA2
mediated rarefaction has yet to be determined.
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Additionally, regardless of the

mechanism by which the delayed rarefaction occurred, there was a significant blunting
of microvessel loss. This speaks to interplay between early and late rarefaction. It’s
possible that the early loss of microvessels through the thromboxane mediated process
in some way primes the system for the later loss. Alternatively, it’s additionally possible
that TxA2 elevations in some way sensitize the system to a greater need of NO for
maintenance of microvessel density, essentially altering the gain of the system with
regards to NO sensitivity and microvessel sparing.

Regardless of the mechanism,

interplay is apparent as there are obvious effects of blocking early rarefaction on
subsequent later microvessel loss.
The supplementary document mentioned in the introduction of this dissertation,
“Aspirin Resistance with Genetic Dyslipidemia: Contribution of Vascular Thromboxane
Generation” by Frisbee et al. serves as a cautionary to target selection. Aspirin therapy
is one of the most commonly prescribed prophylaxes in the world today (5). Numerous
studies have demonstrated the ability to increase the likelihood of survivability of major
cardiac events in those individuals on a chronic, low-dose, aspirin regimen (2-6).
Aspirin serves in this capacity through its ability as a COX-2 inhibitor, decreasing TxA2
production by platelets and diminishing platelet aggregation with the result of reducing
chance of thrombus formation (2). Based on this work, COX-2 selective drugs have
been developed for the purpose of prophylaxis primarily in individuals with some form of
chronic inflammatory disease. What has received significant media attention is the
voluntary recall of the selective COX-2 inhibitor Vioxx which was found to significantly
increase the probability of negative outcomes from a major cardiovascular event. To
many, this finding was unsurprising since you lose the contributions of prostacyclin,
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prostaglandins and thromboxane in the regulation of vascular tone through this highly
upstream inhibition. Where Appendix II serves as a cautionary is in its demonstration of
dyslipidemic mice to lose sensitivity to chronic aspirin therapies. Essentially, after any
significant period of time with profound dyslipidemia, in mice, the prophylaxis with
Aspirin loses any therapeutic value. While studies have to be performed in a fully
vested model of metabolic syndrome, logical extension is that since these animals
demonstrate similarly profound dyslipidemia, a similar resistant phenotype will emerge.
Additionally, since the vasomotor and network consequences of COX metabolites
seems to stem from an imbalance in their production as opposed to a uniform
overproduction of all COX metabolites, more selective downstream targets will logically
have greater therapeutic potential.
Conjecture based on the data presented within this work leads to the following
conclusions. There are significant consequences to the peripheral vasculature resulting
from an imbalance of COX metabolites with moderately diminished prostacyclin
production and sensitivity coupled with drastically elevated TxA2 production resulting in
enhanced vascular tone, blunted dilator responses, increased vessel wall stiffness and
profound microvascular rarefaction.

Evidence from clinical trials indicates that the

adverse effects of chronic COX inhibition severely outweigh therapeutic potential.
Additionally, animal models of dyslipidemia whose lipid levels mimic those found in
metabolic syndrome models demonstrate the very real potential of chronic COX
therapies being ineffectual with time as a resistant phenotype emerges.

Metabolic

syndrome individuals require a better therapeutic target for therapies to disrupt these
COX mediated effects.

In the short term, the answers would seem to come from
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antagonism of the TxA2 dependent pathways which have been shown to protect against
rarefaction and blunted dilator responses in animal models of metabolic syndrome.
While the above mentioned therapies show promise for the short-term, where
they fail is in a mechanistic understanding of the cause of alterations in COX metabolite
balance.

Inhibition of the TxA2 pathway still does improve the production of

prostacyclin. While a more physiologic ratio of TxA2 to prostacyclin may be achievable
simply through TxA2 pathway antagonism, this doesn’t correct the diminished sensitivity
of the system to prostacyclin. Chronic anti-oxidant therapies demonstrate the ability to
confer partial protection against rarefaction along with partial restoration of normal
vasomotor responses while also returning sensitivity of the system to prostacyclin. This
combined with similar effects of anti-inflammatory drugs would indicate that while the
processes of vascular dysfunction are resulting from alterations to COX metabolite
balances, the origin of the problem is not in AA metabolism but rather the effects of
chronic inflammation and elevations in oxidant stress on the system. Further studies
are required to determine the origins of this inflammation and oxidant stress to begin to
truly treat the root of a problem that appears to extend significantly beyond AA
metabolism.
Additionally, future studies need to redouble their efforts on the understanding of
metabolic syndrome related skeletal muscle microvascular rarefaction. Work by Frisbee
et al. has demonstrated that in the obese Zucker rat, when allowed to reach fully
established metabolic syndrome symptomology, even a fully dilated vascular bed is
incapable of matching perfusion with increased metabolic demand resulting in more
rapid rates of fatigue and reduced maximal muscle tension development (1).
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This

inability to match metabolic demand with perfusion is a hallmark of metabolic syndrome
and is too readily attributed to the complex interplay of vasomotor regulators. While
there is no doubt that the dysregulation of the vasomotor plays a significant role in
demand:perfusion impairment, the ability to adequately repair a complex system such
as regulation of vascular tone will require extensive further studies. On the contrary,
making sure there is adequate tissue capillarity to maintain bulk flow though may be a
much more correctable problem. Rarefaction itself has largely been ignored owing to
the fact that tissues work with a surplus capillarity and even when working with a deficit,
the ability to regulate tone allows a tissue to maintain adequate perfusion much more
readily than if vessels were passive. This fails to take into account that with each
capillary lost, the error term for proper vasomotor regulation must become
proportionately smaller to maintain normal flow.

The caveat being that if tissue

capillarity can be spared, this error term can afford to remain much larger.

Taken

together these data suggest that further investigations into understanding the underlying
mechanisms resulting in elevations in oxidant stress and inflammatory status are
essential to understanding the true cause of obesity related vascular disease and that it
is only through an understanding of the origins of these problems that a true therapeutic
regimen against these multi-faceted vasculopathies can be developed.
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purposes include:
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−
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200 system. Additionally, I aided in interpreting the data generated by the
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Research Assistant I, Thomas Elliott’s Lab, W.V.U.
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responses as a result of attainment and maintenance of a profoundly obese state. This
state of obesity, along with the accompanying constellation of comorbidities
(atherogenic dyslipidemia, prothrombotic environment, pro-oxidant environment,
hypertrigylceridemia, hyperlipidemia, insulin resistance, hypertension, etc.) causes
complex changes to the vasculature of afflicted animals and individuals. My current
research tries to define the relationships between changes to the inflammatory profile,
oxidant environment, vascular metabolism of arachidonic acid & the ultimate
consequent alterations to structure, function and perfusion-control within peripheral
vascular networks.
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print]
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of Vascular Research. 2010;47(1):23-34. [Epub 2009 Aug 6]. PMID: 19672105
11. A.G. Goodwill, P.A. Stapleton, M.E. James, J.C. Frisbee. Increased Arachidonic
Acid-Induced Thromboxane Generation Impairs Skeletal Muscle Arteriolar
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12. A.G. Goodwill, M.E. James, J.C. Frisbee. Increased vascular thromboxane
generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with
reduced oxygen tension. Am J Physiol Heart Circ Physiol. 2008
Oct;295(4):H1522-8. Epub 2008 Aug 8. PMID: 18689495
13. P.A. Stapleton, A.G. Goodwill, M.E. James, J.C. Frisbee. Altered Mechanisms
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Hypercholesterolemia. Am J Physiol Regul Integr Comp Physiol. 2007
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14. Amy M. Jones, Adam Goodwill and T. Elliott. Limited Role for the DsrA and
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CONFERENCE PRESENTATIONS
1. Invited Lecture: Tumor necrosis factor alpha contributes to vascular dysfunction
and skeletal muscle microvascular rarefaction in the obese Zucker rat. A.G.
Goodwill, J.T. Butcher, J.C. Frisbee. Experimental Biology 2011/Microcirculatory
Society President’s Symposium II, Washington D.C., District of Columbia, United
States, 2011-04; Abstract 636.16
2. Poster: Temporal progression of microvascular rarefaction in the metabolic
syndrome.
A.G. Goodwill, J.C. Frisbee. Experimental Biology 2011,
Washington D.C., District of Columbia, United States, 2011-04; Abstract 636.17
3. Poster: Differential impact of myogenic activation on dilator responses in cerebral
and skeletal muscle resistance arterioles of obese Zucker rats. J.T. Butcher,
A.G. Goodwill, J.C. Frisbee. Experimental Biology 2011, Washington D.C.,
District of Columbia, United States, 2011-04; Abstract 816.9
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I.M. Olfert. Experimental Biology 2011, Washington D.C., District of Columbia,
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James and J.C. Frisbee. Experimental Biology 2009, New Orleans, Louisiana,
United States. 2009-04; Abstract 23:767.9.
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Louisiana, United States. 2009-04; Abstract 23:766.3.
16. Poster: Development of a predictive model for negative microvascular outcomes
in the metabolic syndrome. J.C. Frisbee, A.G. Goodwill, M.E. James, R.W.
Brock, J.M. Hollander and S.J. Frisbee. Experimental Biology 2009, New
Orleans, Louisiana, United States. 2009-04; Abstract 23:594.11.
17. Poster: Mechanistic links between the lung and the systemic microcirculation
after nanoparticle exposure. T.R. Nurkiewicz, M. Donlin, A.F. Hubbs, A.G.
Goodwill, J.C. Frisbee, B.T. Chen, D.G. Frazer and V. Castranova. Society of
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Toxicology, Baltimore, Maryland, United States. Toxicological Sciences, March
108 (1-S), 1353, 2009.
18. Poster: Diesel exhaust exposure alters microvascular blood flow and wall shear
rate. K.L. Sites, A.G. Goodwill, J.C. Frisbee and T.R. Nurkiewicz. Society of
Toxicology, Baltimore, Maryland, United States. March 108 (1-S), 200, 2009.
19. Invited Lecture: Metabolic Syndrome and Microvascular Rarefaction:
Contributions from Nitric Oxide and Inflammation. J.C. Frisbee, A.G. Goodwill,
P.A. Stapleton, M.E. James, R.W. Bryner, and S.J. Frisbee. The 25th
Conference of the European Society for Microcirculation; Integrating Vascular
Biology and Medicine, Budapest, Hungary. 2008-08
20. Invited Lecture: Microvascular Adaptations to Obesity and the Metabolic
Syndrome. J. Frisbee, A.G. Goodwill, M. James, R. Bryner, S. Frisbee. 2008
APS Intersociety Meeting: The Integrative Biology of Exercise V, Hilton Head,
South Carolina, United States. 2008-08
21. Invited Lecture: The Metabolic Syndrome and Microvascular Rarefaction:
Integrated Model for NO Bioavailability. J.C. Frisbee, A.G. Goodwill, P.A.
Stapleton, M.E. James, R.W. Bryner, S.J. Frisbee European Society for
Microcirculation Annual Meeting 2008, Budapest, Hungary. 2008-08
22. Poster: Dental Habits Related to Adult Cardiovascular Disease and Systemic
Inflammation. S.J. Frisbee, C.B. Chambers, J.C. Frisbee, A.G. Goodwill, R.J.
Crout. The International Association for Dental Research (IADR) 37th Annual
Meeting & Exhibition, Dallas, Texas, United States. 2008-04
23. Poster: Dental health, cardiovascular disease risk and systemic inflammation in
children. C.B. Chambers, S.J. Frisbee, J.C. Frisbee, A.G. Goodwill and R.J.
Crout. The International Association for Dental Research (IADR) 37th Annual
Meeting & Exhibition, Dallas, Texas, United States. 2008-04
24. Poster: Arachidonic acid-induced vascular thromboxane generation in mouse
models of atherothrombotic vascular disease. J.C. Frisbee, M.E. James, A.G.
Goodwill and C. Khamare. 2007-05
25. Poster: Influences of age and gender on cardiovascular disease risk factor
associated inflammation. S.J. Frisbee, A.G. Goodwill, J.M. Delp and J.C.
Frisbee. American Heart Association, Epidemiology Council Meeting, 2007,
Orlando, Florida, United States. 2007-02
26. Poster: Altered Patterns of Inflammatory Marker Expression in Plasma of Obese
vs. Dyslipidemic Humans. S.J. Frisbee, A.G. Goodwill, M. Boegehold, W.A.
Neal, J.C. Frisbee. North American Association for the study of obesity (NAASO)
Annual Scientific Meeting, Boston, Massachusetts, United States. 2006-10
27. Invited Lecture: Inflammation, NO bioavailability and the metabolic syndrome:
interactions leading to rarefaction. J.C. Frisbee, A.G. Goodwill and S.J. Frisbee.
Workshop on Mathematical Modeling of Microcirculation; Mathematical
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Biosciences Institute at Ohio State University, Columbus, Ohio, United States.
2006-10
28. Poster: Low Vascular NO Bioavailability-Induced Microvascular Rarefaction is not
Associated with Angiostatin. J.C. Frisbee, M.E. James, J. Balch Samora, A.G.
Goodwill, B. Chelladurai and D.P. Basile. Arteriosclerosis, Thrombosis and
Vascular Biology 2006 Scientific Sessions, Washington D.C., District of
Columbia, United States. 2006-04
29. Lecture: Regulation of RpoS in enteric bacteria. Hirsch, M., A.M. Jones, A.
Goodwill & T. Elliott. The Seventh Analytical Genetics Meeting, San Diego,
California, United States. 2005-10
30. Lecture: Production of Green Sheen Differs Depending Upon Atmospheric
Conditions and Medium Formulations. Adam G. Goodwill, Heather A. O'Leary,
Amanda M. Hartle, Kate H. Eggleton, and Douglas M. Smith. 2003-04
31. Poster: Identification of the Green Sheen Gene In Uropathogenic E. coli.
Essandoh, Eugene, Leonard Kotevski, Heather O’Leary, Adam Goodwill, Carrie
Martz, Josh Yeykal, Rebhecca Parisi, Kate Eggleton, Douglas M. Smith.
Commonwealth of Pennsylvania University Biologists 34th Annual Meeting,
Shippensburg, Pennsylvania, United States. 2003-04
32. Poster: Production of Green Sheen Differs Depending on Atmospheric
Conditions and EMB Medium Formulations. Adam G. Goodwill, Heather A.
O'Leary, Douglas M. Smith, Ph.D. 2002 Annual meeting of the Allegheny Branch
of the American Society for Microbiology, Clarion, Pennsylvania, United States.
2002-10
33. Poster: Production Of Green Sheen Differs Depending Upon Atmospheric
Conditions and Medium Formulations. Goodwill, A.G., H. A. O’Leary, A. M.
Hartle, K. H. Eggleton and D. M. Smith. Commonwealth of Pennsylvania
University Biologists 33rd Annual Meeting, Lock Haven, Pennsylvania, United
States. 2002-04
INSTITUTIONAL PRESENTATIONS
1. Lecture: Microvascular Rarefaction in the Metabolic Syndrome: Goodwill A.G.
The Department of Physiology & Pharmacology Julie Betschard Symposium
2011-05
2. Invited Lecture: Temporal Progression of Microvascular Rarefaction in the
Metabolic Syndrome: Goodwill A.G. The West Virginia University 2011 E.J. Van
Liere Memorial Convocation and Research Day. 2011-03
3. Lecture: Temporal Progression of Microvascular Rarefaction in the Metabolic
Syndrome: Goodwill A.G. The Department of Physiology and Pharmacology
required annual seminar. 2011-02.
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4. Invited Lecture: Microvascular Rarefaction in the Obese Zucker Rat: Goodwill
A.G. The West Virginia University School of Pharmacy Research Day. 2010-10.
5. Lecture: Increased Vascular Generation of Thromboxane A2: An Initiating
Condition For Microvascular Rarefaction in Obese Zucker Rats? Goodwill A.G.
The Department of Physiology & Pharmacology Julie Betschard Symposium.
2010-05
6. Lecture: Aspirin Resistance with Genetic Dyslipidemia: Contribution of Vascular
Thromboxane Generation. Goodwill A.G. The Department of Physiology and
Pharmacology required annual seminar. 2010-04
7. Lecture: Vascular Consequences of Obesity Induced Alterations to Arachidonic
Acid Metabolism in Obese Zucker Rats. Goodwill A.G. The West Virginia
University Center for Cardiovascular and Respiratory Sciences monthly work in
progress meeting. 2009-12
8. Lecture: Impact of Chronic Anti-Cholesterol Therapy on Development of
Microvascular Rarefaction in the Metabolic Syndrome. Goodwill A.G. The
Department of Physiology and Pharmacology required annual seminar. 2009-09
9. Lecture: Increased Vascular Thromboxane Generation Restrains Arteriolar
Dilation to Hypoxia in Obese Zucker Rats. Goodwill A.G. The Department of
Physiology & Pharmacology Julie Betschard Symposium. 2009-05
10. Poster: Elevated Vascular Thromboxane Generation Impairs Dilation of OZR
Arterioles with Reduced O2 Tension. Goodwill A.G. The West Virginia University
2009 E.J. Van Liere Memorial Convocation and Research Day.2009-04
11. Lecture: Arachidonic Acid-Induced TxA2 Generation Impairs Arteriolar Dilation
with Genetic Dyslipidemia. Goodwill A.G.. The Department of Physiology &
Pharmacology Julie Betschard Symposium. 2008-05
12. Lecture: Increased Arachidonic Acid-Induced Thromboxane Generation Impairs
Skeletal Muscle Arteriolar Dilation with Genetic Dyslipidemia. Goodwill A.G. The
Department of Physiology and Pharmacology required annual seminar. 2008-04
TEACHING EXPERIENCE
− Special Topics in Physiology; West Virginia University
2009
• I facilitated a study group in which specific topics including cardiovascular,
respiratory, and renal physiology were expanded from the perspective of
clinical relevance. This course, designed for medical students, sought to
integrate clinical case studies with the basic biomedical sciences required
to understand the processes of the pathologies presented within those
studies. This course was facilitated by 3 separate instructors.
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− Cardiovascular Physiology Study Session; West Virginia University 2008-2009
• Facilitated a 3 to 5 hour per week study group to aid select pharmacy
professional students in increasing their understanding of cardiovascular
physiology. I was asked to facilitate this tutoring group by the Pharmacy
department. This was only offered during the cardiovascular modules of
their normal coursework each year.
− Genetics Study Session; Clarion University
2002-2003
• Co-taught a supplementary course designed to complement didactic
materials for the genetics course which was required for all
undergraduates in a biology discipline at Clarion University. This course
reinforced concepts taught within the undergraduate genetics curriculum.
INSTITUTIONAL SERVICE
1. Graduate Student Representative, West Virginia University Vice President for
Research and Development Search Committee; 2011
2. Student Member, West Virginia University Vice President for Health Sciences
Research and Graduate Education Search Committee; 2010
SERVICE TO SCIENTIFIC SOCIETIES
1. Microcirculatory Society Young Investigator Symposium Co-Chair. Experimental
Biology, Washington D.C., District of Columbia, United States.
2011-04
AWARDS & FELLOWSHIPS
1. Runner up, Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of
Physiology and Pharmacology
2011
2. Runner up, American Society for Pharmacology and Experimental Therapeutics
Cardiovascular Section Graduate Student Best Abstract Award
2011
3. Society for Experimental Biology and Medicine, Burton E. Sobel Award for
Excellence in Cardiovascular Research
2011
4. American Society for Pharmacology and Experimental Therapeutics Graduate
Student Travel Award; Experimental Biology
2011
5. Runner up, Best Oral Presentation The West Virginia University E.J. Van Liere
Memorial Convocation/
2011
6. Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of Physiology
and Pharmacology
2010
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7. ORAU-Fellowship for 60th Annual Lindau Meeting of Nobel Laureates in
Chemistry, Physics, and Physiology/Medicine Lindau, Germany
2010
8. American Heart Association – Great Rivers Affiliate “Early
Microvascular
Rarefaction in Metabolic Syndrome” 10PRE3040016
2010-2012
9. Research Training in Cardiovascular and Pulmonary Diseases (Predoctoral
Fellowship) 5T32HL090610-02.
2009-2010
10. Best Oral Presentation, Julie Betschart Symposium W.V.U. Dept of Physiology
and Pharmacology
2009
11. Zweifach Student Travel Award, Microcirculatory Society
2009
12. Best Oral Presentation CPUB
2003
13. Best Poster Presentation CPUB
2002
14. Runner up, Best Poster Presentation ABASM
2002
PROFESSIONAL SOCIETY MEMBERSHIPS
1. Society for Experimental Biology & Medicine, 2011 (Student Member)
2. American Physiological Society, 2011 (Student Member)
3. American Society for Pharmacology and Experimental Therapeutics, 2011
(Student Member)
4. Microcirculatory Society, USA 2009-2011 (Student Member)
5. American Society for Microbiology 2001-2003 (Student Member)
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